methylarsonic acid - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	methylarsonic acid	go back to main search page
Accession:	CHEBI:29852	browse the term
Definition:	An arsonic acid that has formula CH5AsO3.
Synonyms:	related_synonym:	Formula=CH5AsO3; InChI=1S/CH5AsO3/c1-2(3,4)5/h1H3,(H2,3,4,5); InChIKey=QYPPRTNMGCREIM-UHFFFAOYSA-N; MAA; MeAsO(OH)2; SMILES=C[As](O)(O)=O; methanearsonic acid; monomethylarsonic acid
	alt_id:	CHEBI:25221; CHEBI:6865
	xref:	Beilstein:1739373; CAS:124-58-3; Gmelin:1316748; KEGG:C07294
	xref_mesh:	MESH:C020300
	xref:	PPDB:1575
	cyclic_relationship:	is_conjugate_acid_of CHEBI:33409

show annotations for term's descendants Sort by:
Rat (619) Mouse (730) Human (637) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (730)

methylarsonic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of A2ML1 mRNA

NCBI chr 6:121,612,920...121,656,197
Ensembl chr 6:121,612,335...121,656,186

G

acetoacetyl-CoA synthetase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AACS mRNA

NCBI chr 5:125,552,937...125,594,469
Ensembl chr 5:125,552,878...125,594,474

G

alanine and arginine rich domain containing protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AARD mRNA

NCBI chr15:51,903,503...51,909,118
Ensembl chr15:51,903,503...51,909,118

G

cDNA sequence AB124611

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AB124611 mRNA

NCBI chr 9:21,437,410...21,456,629
Ensembl chr 9:21,437,472...21,456,629

G

ATP-binding cassette, sub-family B member 1A

increases expression

monomethylarsonic acid results in increased expression of ABCB1A mRNA; monomethylarsonic acid results in increased expression of ABCB1A protein

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

ATP-binding cassette, sub-family C member 1

increases expression
affects expression

monomethylarsonic acid results in increased expression of ABCC1 mRNA; monomethylarsonic acid results in increased expression of ABCC1 protein
monomethylarsonic acid affects the expression of ABCC1 mRNA

PMID:16436460 PMID:24091636

NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601

G

ATP-binding cassette, sub-family member 2

increases expression

monomethylarsonic acid results in increased expression of ABCC2 mRNA; monomethylarsonic acid results in increased expression of ABCC2 protein

PMID:16436460 PMID:24091636

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

G

ATP-binding cassette, sub-family C member 3

increases expression

monomethylarsonic acid results in increased expression of ABCC3 mRNA; monomethylarsonic acid results in increased expression of ABCC3 protein

NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823

G

ATP binding cassette subfamily G member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ABCG3 mRNA

NCBI chr 5:105,082,924...105,130,675
Ensembl chr 5:105,082,923...105,130,584

G

ArfGAP with coiled-coil, ankyrin repeat and PH domains 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACAP1 mRNA

NCBI chr11:69,772,393...69,786,390
Ensembl chr11:69,772,393...69,786,365

G

acyl-CoA thioesterase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACOT1 mRNA

NCBI chr12:84,056,276...84,064,444
Ensembl chr12:84,056,264...84,065,145

G

acyl-CoA thioesterase 12

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACOT12 mRNA

NCBI chr13:91,889,635...91,934,271
Ensembl chr13:91,889,631...91,934,267

G

acyl-Coenzyme A oxidase 2, branched chain

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACOX2 mRNA

NCBI chr14:14,210,406...14,244,262
Ensembl chr14:14,210,420...14,244,262

G

proacrosin binding protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ACRBP mRNA

NCBI chr 6:125,026,890...125,040,228
Ensembl chr 6:125,026,652...125,040,230

G

ADAM metallopeptidase with thrombospondin type 1 motif 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADAMTS4 mRNA

NCBI chr 1:171,077,698...171,089,836
Ensembl chr 1:171,077,990...171,088,206

G

ADAM metallopeptidase with thrombospondin type 1 motif 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ADAMTS6 mRNA

NCBI chr13:104,423,026...104,633,203
Ensembl chr13:104,424,343...104,633,203

G

adhesion G protein-coupled receptor G1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ADGRG1 mRNA

NCBI chr 8:95,701,321...95,740,836
Ensembl chr 8:95,701,379...95,740,845

G

adrenomedullin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADM mRNA

NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027

G

adrenergic receptor, alpha 2b

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADRA2B mRNA

NCBI chr 2:127,205,099...127,209,141
Ensembl chr 2:127,205,128...127,209,141

G

adrenergic receptor, beta 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ADRB1 mRNA

NCBI chr19:56,710,549...56,713,582
Ensembl chr19:56,710,631...56,721,545

G

adrenergic receptor, beta 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADRB2 mRNA

NCBI chr18:62,310,784...62,313,052
Ensembl chr18:62,310,887...62,313,030

G

AF4/FMR2 family, member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AFF3 mRNA

NCBI chr 1:38,212,936...38,704,036
Ensembl chr 1:38,216,407...38,704,036

G

alpha fetoprotein

increases expression

monomethylarsonic acid results in increased expression of AFP mRNA

NCBI chr 5:90,638,573...90,656,766
Ensembl chr 5:90,638,596...90,656,766

G

anterior gradient 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AGR3 mRNA

NCBI chr12:35,975,620...35,999,736
Ensembl chr12:35,975,619...35,999,735

G

AT hook, DNA binding motif, containing 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AHDC1 mRNA

NCBI chr 4:132,738,797...132,805,421
Ensembl chr 4:132,738,571...132,805,421

G

aryl-hydrocarbon receptor

multiple interactions

AHR mutant form inhibits the reaction [monomethylarsonic acid results in increased expression of CYP1A1 protein]; monomethylarsonic acid results in decreased expression of and affects the localization of AHR protein

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

adenylate kinase 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AK4 mRNA

NCBI chr 4:101,273,675...101,324,968
Ensembl chr 4:101,276,474...101,324,192

G

alkaline phosphatase 3, intestine, not Mn requiring

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AKP3 mRNA

NCBI chr 1:87,052,676...87,056,450
Ensembl chr 1:87,052,695...87,055,634

G

aldo-keto reductase family 7, member A5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AKR7A5 mRNA

NCBI chr 4:139,038,005...139,046,097
Ensembl chr 4:139,038,055...139,045,737

G

thymoma viral proto-oncogene 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of AKT1 mRNA

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

aldolase C, fructose-bisphosphate

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ALDOC mRNA

NCBI chr11:78,213,899...78,218,607
Ensembl chr11:78,213,794...78,218,607

G

alpha-kinase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ALPK1 mRNA

NCBI chr 3:127,460,367...127,574,195
Ensembl chr 3:127,463,959...127,574,176

G

angiopoietin-like 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANGPTL7 mRNA

NCBI chr 4:148,579,737...148,584,919
Ensembl chr 4:148,579,640...148,584,917

G

ankyrin repeat domain 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANKRD1 mRNA

NCBI chr19:36,089,365...36,097,244
Ensembl chr19:36,089,361...36,097,499

G

ANKRD40 C-terminal like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANKRD40CL mRNA

NCBI chr11:94,172,665...94,177,086
Ensembl chr11:94,172,699...94,177,079

G

annexin A8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANXA8 mRNA

NCBI chr14:33,807,936...33,822,528
Ensembl chr14:33,807,938...33,822,528

G

apolipoprotein L 7a

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of APOL7A mRNA

NCBI chr15:77,272,417...77,283,310
Ensembl chr15:77,272,419...77,283,310

G

apolipoprotein L 9a

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of APOL9A mRNA

NCBI chr15:77,287,989...77,295,280
Ensembl chr15:77,287,989...77,295,335

G

amphiregulin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AREG mRNA

NCBI chr 5:91,287,458...91,296,291
Ensembl chr 5:91,287,458...91,296,291

G

Rho GTPase activating protein 15

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP15 mRNA

NCBI chr 2:43,638,786...44,285,965
Ensembl chr 2:43,638,836...44,285,965

G

Rho GTPase activating protein 25

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP25 mRNA

NCBI chr 6:87,435,526...87,510,241
Ensembl chr 6:87,435,527...87,510,241

G

Rho GTPase activating protein 30

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP30 mRNA

NCBI chr 1:171,216,528...171,237,808
Ensembl chr 1:171,216,522...171,237,866

G

Rho GTPase activating protein 45

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP45 mRNA

NCBI chr10:79,852,505...79,867,305
Ensembl chr10:79,852,487...79,867,306

G

Rho GTPase activating protein 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP8 mRNA

NCBI chr15:84,604,214...84,657,058
Ensembl chr15:84,604,253...84,656,408

G

Rho, GDP dissociation inhibitor beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGDIB mRNA

NCBI chr 6:136,900,653...136,918,895
Ensembl chr 6:136,900,653...136,918,897

G

Rho guanine nucleotide exchange factor 38

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ARHGEF38 mRNA

NCBI chr 3:132,818,039...132,940,710
Ensembl chr 3:132,818,039...132,940,710

G

ADP-ribosylation factor-like 5C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARL5C mRNA

NCBI chr11:97,880,404...97,887,109
Ensembl chr11:97,880,404...97,887,007

G

ADP-ribosylation factor-like 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ARL9 mRNA

NCBI chr 5:77,146,054...77,158,806
Ensembl chr 5:77,151,902...77,158,453

G

arsenite methyltransferase

increases metabolic processing
increases chemical synthesis
multiple interactions
increases expression

AS3MT protein polymorphism results in increased metabolism of monomethylarsonic acid; AS3MT protein results in increased metabolism of monomethylarsonic acid
AS3MT protein results in increased chemical synthesis of monomethylarsonic acid
[AS3MT gene polymorphism affects the susceptibility to Arsenic] which results in increased abundance of monomethylarsonic acid; [AS3MT protein polymorphism results in increased metabolism of arsenite] which results in increased chemical synthesis of monomethylarsonic acid; [AS3MT protein polymorphism results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of Cacodylic Acid; [AS3MT protein polymorphism results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of dimethylarsinous acid; [AS3MT protein results in increased metabolism of arsenite] which results in increased chemical synthesis of monomethylarsonic acid; [AS3MT protein results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of Cacodylic Acid; [AS3MT protein results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of dimethylarsinous acid
monomethylarsonic acid results in increased expression of AS3MT protein

PMID:22005461 PMID:22868225 PMID:24845704 PMID:36399430

NCBI chr19:46,695,124...46,729,538
Ensembl chr19:46,695,897...46,729,538

G

ankyrin repeat and SOCS box-containing 14

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ASB14 mRNA

NCBI chr14:26,616,547...26,638,393
Ensembl chr14:26,616,514...26,637,215

G

ankyrin repeat and SOCS box-containing 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ASB4 mRNA

NCBI chr 6:5,383,386...5,433,022
Ensembl chr 6:5,383,386...5,433,022

G

aspartic peptidase, retroviral-like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ASPRV1 mRNA

NCBI chr 6:86,605,216...86,606,692
Ensembl chr 6:86,605,146...86,606,692

G

ataxia, cerebellar, Cayman type, opposite strand

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ATCAYOS mRNA

NCBI chr10:81,030,525...81,044,204
Ensembl chr10:81,030,443...81,046,711

G

activating transcription factor 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ATF3 mRNA

NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236

G

activating transcription factor 7 interacting protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ATF7IP2 mRNA

NCBI chr16:10,010,513...10,068,595
Ensembl chr16:10,010,576...10,069,342

G

ATPase, class V, type 10D

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ATP10D mRNA

NCBI chr 5:72,360,672...72,456,114
Ensembl chr 5:72,360,672...72,456,118

G

ATPase, Cu++ transporting, beta polypeptide

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ATP7B mRNA

NCBI chr 8:22,482,799...22,550,347
Ensembl chr 8:22,482,801...22,550,321

G

UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of B3GALT5 mRNA

NCBI chr16:96,037,001...96,121,059
Ensembl chr16:96,037,001...96,121,059

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of B3GNT5 mRNA

NCBI chr16:19,578,943...19,591,508
Ensembl chr16:19,578,958...19,591,503

G

B cell scaffold protein with ankyrin repeats 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BANK1 mRNA

NCBI chr 3:135,759,124...136,031,902
Ensembl chr 3:135,759,124...136,031,827

G

BTG3 associated nuclear protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of BANP mRNA

NCBI chr 8:122,674,711...122,755,999
Ensembl chr 8:122,676,489...122,755,997

G

BCL6 co-repressor-like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of BCORL1 mRNA

NCBI chr X:47,430,235...47,496,945
Ensembl chr X:47,430,235...47,496,926

G

bifunctional apoptosis regulator

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of BFAR mRNA

NCBI chr16:13,489,722...13,521,476
Ensembl chr16:13,489,722...13,521,476
Ensembl chr16:13,489,722...13,521,476

G

basic helix-loop-helix family, member e41

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BHLHE41 mRNA

NCBI chr 6:145,803,969...145,811,146
Ensembl chr 6:145,803,969...145,811,284

G

B lymphoid kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BLK mRNA

NCBI chr14:63,610,286...63,654,636
Ensembl chr14:63,610,285...63,654,486

G

basic helix-loop-helix ARNT like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of BMAL1 mRNA

NCBI chr 7:112,777,820...112,913,333
Ensembl chr 7:112,806,672...112,913,333

G

Bri3 binding protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BRI3BP mRNA

NCBI chr 5:125,518,632...125,537,949
Ensembl chr 5:125,518,632...125,537,434

G

Bruton agammaglobulinemia tyrosine kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BTK mRNA

NCBI chr X:133,443,083...133,484,366
Ensembl chr X:133,443,085...133,484,319

G

B and T lymphocyte associated

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BTLA mRNA

NCBI chr16:45,043,121...45,073,258
Ensembl chr16:45,044,678...45,078,033

G

C1q and tumor necrosis factor related protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of C1QTNF3 mRNA

NCBI chr15:10,952,418...10,980,248
Ensembl chr15:10,952,418...10,980,236

G

complement component 4 binding protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of C4BP mRNA

NCBI chr 1:130,562,510...130,589,365
Ensembl chr 1:130,562,510...130,589,369

G

calcium channel, voltage-dependent, alpha 1I subunit

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CACNA1I mRNA

NCBI chr15:80,171,439...80,282,493
Ensembl chr15:80,171,439...80,282,480

G

calcium/calmodulin-dependent protein kinase I gamma

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CAMK1G mRNA

NCBI chr 1:193,028,654...193,052,636
Ensembl chr 1:193,028,654...193,052,606

G

calpain 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CAPN3 mRNA

NCBI chr 2:120,294,074...120,335,400
Ensembl chr 2:120,294,053...120,335,399

G

caspase recruitment domain family, member 11

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CARD11 mRNA

NCBI chr 5:140,858,109...140,986,398
Ensembl chr 5:140,858,745...140,986,337

G

capping protein regulator and myosin 1 linker 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CARMIL2 mRNA

NCBI chr 8:106,412,642...106,424,827
Ensembl chr 8:106,412,906...106,424,819

G

caspase 3

affects response to substance
multiple interactions
increases expression

CASP3 protein affects the susceptibility to monomethylarsonic acid
[monomethylarsonic acid co-treated with Buthionine Sulfoximine] results in increased activity of CASP3 protein
monomethylarsonic acid results in increased expression of CASP3 mRNA
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of CASP3 mRNA

PMID:15963344 PMID:17481689 PMID:23192986

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

catalase

multiple interactions

[CAT protein results in decreased oxidation of monomethylarsonous acid] which results in decreased chemical synthesis of monomethylarsonic acid

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

cation channel, sperm associated 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CATSPER4 mRNA

NCBI chr 4:133,939,276...133,954,743
Ensembl chr 4:133,939,281...133,954,694

G

coiled-coil domain containing 122

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC122 mRNA

NCBI chr14:77,274,212...77,349,703
Ensembl chr14:77,274,212...77,349,697

G

coiled-coil domain containing 162

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC162 mRNA

NCBI chr10:41,414,838...41,592,586
Ensembl chr10:41,414,842...41,592,630

G

coiled-coil domain containing 71 like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CCDC71L mRNA

NCBI chr12:32,428,788...32,432,942
Ensembl chr12:32,428,703...32,432,942

G

coiled-coil domain containing 78

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC78 mRNA

NCBI chr17:26,005,554...26,009,487
Ensembl chr17:26,005,554...26,009,487

G

coiled-coil domain containing 87

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC87 mRNA

NCBI chr19:4,889,394...4,892,556
Ensembl chr19:4,889,394...4,892,556

G

coiled-coil domain containing 92B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC92B mRNA

NCBI chr11:74,510,428...74,532,342
Ensembl chr11:74,510,431...74,532,342

G

C-C motif chemokine ligand 22

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCL22 mRNA

NCBI chr 8:95,472,312...95,478,016
Ensembl chr 8:95,472,218...95,478,327

G

cellular communication network factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CCN1 mRNA

NCBI chr 3:145,352,726...145,355,740
Ensembl chr 3:145,352,731...145,355,736

G

cyclin D1

increases expression

monomethylarsonic acid results in increased expression of CCND1 mRNA

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

cyclin E1

increases expression

monomethylarsonic acid results in increased expression of CCNE1 mRNA

NCBI chr 7:37,797,409...37,806,915
Ensembl chr 7:37,797,409...37,806,959

G

C-C motif chemokine receptor 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCR6 mRNA

NCBI chr17:8,454,875...8,477,353
Ensembl chr17:8,454,875...8,475,973

G

C-C motif chemokine receptor 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCR7 mRNA

NCBI chr11:99,035,025...99,045,903
Ensembl chr11:99,035,022...99,045,903

G

CD180 antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD180 mRNA

NCBI chr13:102,830,055...102,843,139
Ensembl chr13:102,830,066...102,876,137

G

CD2 antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD2 mRNA

NCBI chr 3:101,183,224...101,195,255
Ensembl chr 3:101,183,215...101,195,255

G

CD22 antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD22 mRNA

NCBI chr 7:30,564,829...30,579,767
Ensembl chr 7:30,564,827...30,579,767

G

CD28 antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD28 mRNA

NCBI chr 1:60,785,547...60,812,521
Ensembl chr 1:60,755,959...60,812,518

G

CD37 antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD37 mRNA

NCBI chr 7:44,883,056...44,888,701
Ensembl chr 7:44,883,056...44,888,539

G

CD40 antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD40 mRNA

NCBI chr 2:164,897,535...164,913,574
Ensembl chr 2:164,897,547...164,914,868

G

CD46 antigen, complement regulatory protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD46 mRNA

NCBI chr 1:194,721,279...194,781,149
Ensembl chr 1:194,719,134...194,774,557

G

CD5 antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD5 mRNA

NCBI chr19:10,695,471...10,716,390
Ensembl chr19:10,694,480...10,716,366

G

CD52 antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD52 mRNA

NCBI chr 4:133,820,849...133,822,384
Ensembl chr 4:133,809,759...133,822,393

G

CD53 antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD53 mRNA

NCBI chr 3:106,666,177...106,697,465
Ensembl chr 3:106,667,237...106,697,465

G

CD55 molecule, opposite strand sequence

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD55OS mRNA

NCBI chr 1:130,350,561...130,365,651
Ensembl chr 1:130,350,561...130,365,651

G

CD6 antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD6 mRNA

NCBI chr19:10,766,703...10,807,427
Ensembl chr19:10,766,705...10,807,422

G

CD69 antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD69 mRNA

NCBI chr 6:129,244,287...129,252,332
Ensembl chr 6:129,244,288...129,252,399

G

CD79A antigen (immunoglobulin-associated alpha)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD79A mRNA

NCBI chr 7:24,596,922...24,601,283
Ensembl chr 7:24,596,806...24,601,622

G

CD79B antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD79B mRNA

NCBI chr11:106,202,167...106,205,388
Ensembl chr11:106,202,167...106,205,588

G

CD83 antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD83 mRNA

NCBI chr13:43,938,661...43,956,608
Ensembl chr13:43,938,251...43,956,608

G

CD84 antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD84 mRNA

NCBI chr 1:171,667,261...171,718,288
Ensembl chr 1:171,667,265...171,718,285

G

CD86 antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD86 mRNA

NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443

G

cell division cycle 25B

decreases activity

monomethylarsonic acid results in decreased activity of CDC25B protein

NCBI chr 2:131,028,356...131,040,431
Ensembl chr 2:131,028,869...131,040,417

G

CDC42 effector protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CDC42EP2 mRNA

NCBI chr19:5,967,584...5,974,844
Ensembl chr19:5,965,664...5,974,844

G

cadherin 1

increases expression

monomethylarsonic acid results in increased expression of CDH1 mRNA

NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878

G

cadherin 2

increases expression

monomethylarsonic acid results in increased expression of CDH2 mRNA

NCBI chr18:16,721,934...16,942,303
Ensembl chr18:16,721,934...16,942,303

G

cyclin dependent kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CDK3 mRNA

NCBI chr11:116,106,828...116,111,113
Ensembl chr11:116,106,829...116,111,113

G

cyclin dependent kinase like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CDKL1 mRNA

NCBI chr12:69,791,944...69,838,057
Ensembl chr12:69,793,622...69,838,041

G

cyclin dependent kinase inhibitor 1A

decreases expression
multiple interactions

monomethylarsonic acid results in decreased expression of CDKN1A mRNA
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of CDKN1A mRNA

PMID:17481689 PMID:23192986

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

CECR2, histone acetyl-lysine reader

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CECR2 mRNA

NCBI chr 6:120,643,275...120,748,152
Ensembl chr 6:120,643,330...120,748,151

G

carboxylesterase 2F

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CES2F mRNA

NCBI chr 8:105,673,987...105,688,264
Ensembl chr 8:105,673,988...105,686,679

G

carboxylesterase 2G

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CES2G mRNA

NCBI chr 8:105,688,350...105,696,169
Ensembl chr 8:105,688,350...105,696,169

G

cilia and flagella associated protein 47

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CFAP47 mRNA

NCBI chr X:78,310,164...78,560,957
Ensembl chr X:78,310,165...78,560,891

G

chondroadherin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CHAD mRNA

NCBI chr11:94,455,873...94,459,953
Ensembl chr11:94,455,873...94,459,953

G

cysteine and histidine rich domain containing 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CHORDC1 mRNA

NCBI chr 9:18,203,563...18,225,296
Ensembl chr 9:18,203,421...18,228,738

G

cholinergic receptor, nicotinic, alpha polypeptide 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CHRNA9 mRNA

NCBI chr 5:66,092,317...66,134,823
Ensembl chr 5:66,092,264...66,134,669

G

carbohydrate sulfotransferase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CHST3 mRNA

NCBI chr10:60,017,349...60,057,936
Ensembl chr10:60,017,354...60,055,082

G

circadian associated repressor of transcription

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CIART mRNA

NCBI chr 3:95,785,812...95,790,012
Ensembl chr 3:95,785,815...95,789,563

G

class II transactivator

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CIITA mRNA

NCBI chr16:10,297,877...10,348,928
Ensembl chr16:10,297,923...10,346,282

G

cartilage intermediate layer protein, nucleotide pyrophosphohydrolase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CILP mRNA

NCBI chr 9:65,172,462...65,187,896
Ensembl chr 9:65,172,462...65,187,887

G

cold inducible RNA binding protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CIRBP mRNA

NCBI chr10:80,001,824...80,008,620
Ensembl chr10:80,001,819...80,008,620

G

chloride channel accessory 3A2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CLCA3A2 mRNA

NCBI chr 3:144,486,340...144,525,385
Ensembl chr 3:144,502,320...144,525,255

G

chloride channel accessory 4B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLCA4B mRNA

NCBI chr 3:144,616,682...144,638,290
Ensembl chr 3:144,616,682...144,638,290

G

cardiotrophin-like cytokine factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLCF1 mRNA

NCBI chr19:4,264,479...4,273,548
Ensembl chr19:4,264,292...4,273,544

G

C-type lectin domain family 2, member e

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CLEC2E mRNA

NCBI chr 6:129,068,779...129,077,866
Ensembl chr 6:129,068,961...129,077,876

G

C-type lectin domain family 2, member i

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLEC2I mRNA

NCBI chr 6:128,864,550...128,875,131
Ensembl chr 6:128,864,551...128,875,130

G

C-type lectin domain family 7, member a

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLEC7A mRNA

NCBI chr 6:129,438,554...129,449,748
Ensembl chr 6:129,438,554...129,449,742

G

clusterin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLU mRNA

NCBI chr14:66,206,093...66,218,992
Ensembl chr14:66,205,932...66,218,996

G

cannabinoid receptor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CNR2 mRNA

NCBI chr 4:135,622,500...135,647,530
Ensembl chr 4:135,622,705...135,647,518

G

cochlin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of COCH mRNA

NCBI chr12:51,640,156...51,652,558
Ensembl chr12:51,640,124...51,652,554

G

collagen, type XI, alpha 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of COL11A2 mRNA

NCBI chr17:34,257,462...34,285,659
Ensembl chr17:34,258,411...34,285,659

G

collagen, type VII, alpha 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of COL7A1 mRNA

NCBI chr 9:108,782,654...108,813,943
Ensembl chr 9:108,782,654...108,813,943

G

collagen like tail subunit of asymmetric acetylcholinesterase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of COLQ mRNA

NCBI chr14:31,245,039...31,299,820
Ensembl chr14:31,245,039...31,313,300

G

coronin, actin binding protein 1A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CORO1A mRNA

NCBI chr 7:126,298,946...126,303,925
Ensembl chr 7:126,298,945...126,306,959

G

coactosin like F-actin binding protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of COTL1 mRNA

NCBI chr 8:120,535,953...120,567,318
Ensembl chr 8:120,535,961...120,567,283

G

cleavage and polyadenylation specific factor 4-like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CPSF4L mRNA

NCBI chr11:113,588,997...113,601,125
Ensembl chr11:113,588,998...113,600,843

G

carboxypeptidase X, M14 family member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CPXM1 mRNA

NCBI chr 2:130,232,695...130,239,549
Ensembl chr 2:130,232,695...130,239,494

G

complement receptor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CR2 mRNA

NCBI chr 1:194,819,120...194,859,096
Ensembl chr 1:194,819,119...194,859,024

G

CDP-L-ribitol pyrophosphorylase A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CRPPA mRNA

NCBI chr12:36,430,334...36,739,502
Ensembl chr12:36,431,449...36,739,502

G

cytotoxic and regulatory T cell molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CRTAM mRNA

NCBI chr 9:40,880,987...40,915,922
Ensembl chr 9:40,880,987...40,915,924

G

cryptochrome circadian regulator 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CRY1 mRNA

NCBI chr10:84,967,564...85,020,918
Ensembl chr10:84,967,564...85,020,928

G

cysteine-serine-rich nuclear protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CSRNP2 mRNA

NCBI chr15:100,377,451...100,393,120
Ensembl chr15:100,377,451...100,393,369

G

catenin alpha 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CTNNA3 mRNA

NCBI chr10:63,265,877...64,841,174
Ensembl chr10:63,265,877...64,839,446

G

C-X-C motif chemokine ligand 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CXCL10 mRNA

NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748

G

C-X-C motif chemokine ligand 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CXCL9 mRNA

NCBI chr 5:92,469,190...92,475,938
Ensembl chr 5:92,469,206...92,475,938

G

cytochrome b-245, beta polypeptide

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CYBB mRNA

NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

AHR mutant form inhibits the reaction [monomethylarsonic acid results in increased expression of CYP1A1 protein]; monomethylarsonic acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of CYP1A1 protein]; monomethylarsonic acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; monomethylarsonic acid results in increased expression of and results in increased activity of CYP1A1 protein
monomethylarsonic acid results in increased expression of CYP1A1 mRNA
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CYP1A1 mRNA

PMID:24161444 PMID:34876320

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression

monomethylarsonic acid results in increased expression of CYP1A2 mRNA

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 2, subfamily b, polypeptide 13

multiple interactions

[monomethylarsonic acid co-treated with Diethylnitrosamine] results in increased expression of CYP2B2 mRNA

NCBI chr 7:25,760,813...25,795,622
Ensembl chr 7:25,760,922...25,795,622

G

cytochrome P450, family 2, subfamily c, polypeptide 52, pseudogene

increases expression

monomethylarsonic acid results in increased expression of CYP2C11 mRNA

NCBI chr19:38,965,106...38,992,071
Ensembl chr19:38,965,091...38,991,733

G

cytochrome P450, family 3, subfamily a, polypeptide 25

increases expression

monomethylarsonic acid results in increased expression of CYP3A25 mRNA

NCBI chr 5:145,914,002...145,946,454
Ensembl chr 5:145,914,004...145,946,428

G

cytochrome P450, family 4, subfamily f, polypeptide 18

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CYP4F18 mRNA

NCBI chr 8:72,742,326...72,763,512
Ensembl chr 8:72,742,326...72,763,470

G

disabled 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DAB1 mRNA

NCBI chr 4:103,476,425...104,602,041
Ensembl chr 4:103,476,556...104,602,041

G

D site albumin promoter binding protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DBP mRNA

NCBI chr 7:45,354,658...45,359,579
Ensembl chr 7:45,354,512...45,359,627

G

doublecortin-like kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DCLK3 mRNA

NCBI chr 9:111,268,149...111,318,679
Ensembl chr 9:111,268,149...111,318,186

G

damage specific DNA binding protein 2

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of DDB2 mRNA

NCBI chr 2:91,041,924...91,067,465
Ensembl chr 2:91,041,917...91,067,327

G

differentially expressed in FDCP 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DEF6 mRNA

NCBI chr17:28,426,752...28,447,582
Ensembl chr17:28,426,752...28,447,582

G

defensin, alpha, 21

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DEFA21 mRNA

NCBI chr 8:21,515,561...21,516,533
Ensembl chr 8:21,515,561...21,516,532

G

defensin, alpha, 22

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DEFA22 mRNA

NCBI chr 8:21,652,293...21,653,265
Ensembl chr 8:21,652,293...21,653,265

G

defensin, alpha, 29

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DEFA29 mRNA

NCBI chr 8:21,815,904...21,817,034
Ensembl chr 8:21,815,903...21,817,036

G

defensin, alpha, 34

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DEFA34 mRNA

NCBI chr 8:22,155,813...22,156,749
Ensembl chr 8:22,155,813...22,156,748

G

defensin, alpha, 36

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DEFA36 mRNA

NCBI chr 8:21,917,444...21,918,402
Ensembl chr 8:21,917,427...21,918,407

G

defensin, alpha, 40

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DEFA40 mRNA

NCBI chr 8:21,739,731...21,740,569
Ensembl chr 8:21,739,770...21,740,572

G

defensin, alpha, 41

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DEFA41 mRNA

NCBI chr 8:21,691,620...21,692,462
Ensembl chr 8:21,691,577...21,692,555

G

defensin, alpha, 42

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DEFA42 mRNA

NCBI chr 8:21,945,443...21,946,533
Ensembl chr 8:21,945,461...21,946,576

G

7-dehydrocholesterol reductase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DHCR7 mRNA

NCBI chr 7:143,376,827...143,402,147
Ensembl chr 7:143,376,882...143,402,147

G

dehydrogenase/reductase 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DHRS9 mRNA

NCBI chr 2:69,210,806...69,233,430
Ensembl chr 2:69,210,789...69,234,877

G

DIRAS family, GTP-binding RAS-like 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DIRAS2 mRNA

NCBI chr13:52,658,411...52,685,390
Ensembl chr13:52,658,416...52,685,315

G

distal-less homeobox 1, antisense

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DLX1AS mRNA

NCBI chr 2:71,360,982...71,368,235
Ensembl chr 2:71,346,798...71,368,252

G

dynein, axonemal, heavy chain 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DNAH10 mRNA

NCBI chr 5:124,802,149...124,911,372
Ensembl chr 5:124,802,149...124,911,372

G

dynein axonemal intermediate chain 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DNAI4 mRNA

NCBI chr 4:102,891,954...102,971,524
Ensembl chr 4:102,895,262...102,971,752

G

DnaJ heat shock protein family (Hsp40) member B13

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DNAJB13 mRNA

NCBI chr 7:100,152,218...100,182,834
Ensembl chr 7:100,150,923...100,164,167

G

DnaJ heat shock protein family (Hsp40) member B3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DNAJB3 mRNA

NCBI chr 1:88,132,454...88,133,470
Ensembl chr 1:88,132,454...88,133,504

G

deoxyribonuclease 1-like 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DNASE1L2 mRNA

NCBI chr17:24,659,054...24,662,075
Ensembl chr17:24,659,055...24,662,079

G

deoxyribonuclease 1-like 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DNASE1L3 mRNA

NCBI chr14:14,475,014...14,504,586
Ensembl chr14:14,475,200...14,505,240

G

dynamin 3, opposite strand

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DNM3OS mRNA

NCBI chr 1:162,045,192...162,053,119
Ensembl chr 1:162,045,192...162,053,119

G

DNA methyltransferase 1

decreases expression

monomethylarsonic acid results in decreased expression of DNMT1 mRNA

NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184

G

dedicator of cytokinesis 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DOCK10 mRNA

NCBI chr 1:80,478,785...80,736,482
Ensembl chr 1:80,478,790...80,736,244

G

dedicator of cyto-kinesis 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DOCK2 mRNA

NCBI chr11:34,176,815...34,674,732
Ensembl chr11:34,176,815...34,674,719

G

docking protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DOK3 mRNA

NCBI chr13:55,671,044...55,678,158
Ensembl chr13:55,671,044...55,677,109

G

dopamine receptor D3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DRD3 mRNA

NCBI chr16:43,574,285...43,646,353
Ensembl chr16:43,574,389...43,643,295

G

dual oxidase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUOX2 mRNA

NCBI chr 2:122,109,727...122,129,221
Ensembl chr 2:122,109,728...122,128,930

G

dual oxidase maturation factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUOXA1 mRNA

NCBI chr 2:122,134,012...122,144,255
Ensembl chr 2:122,132,672...122,144,211

G

dual oxidase maturation factor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUOXA2 mRNA

NCBI chr 2:122,129,381...122,133,088
Ensembl chr 2:122,129,381...122,133,366

G

dual specificity phosphatase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUSP1 mRNA

NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102

G

dual specificity phosphatase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DUSP2 mRNA

NCBI chr 2:127,178,079...127,180,297
Ensembl chr 2:127,178,079...127,180,296

G

dual specificity phosphatase 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUSP6 mRNA

NCBI chr10:99,098,676...99,103,351
Ensembl chr10:99,099,093...99,103,351

G

ELL associated factor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EAF2 mRNA

NCBI chr16:36,613,246...36,695,275
Ensembl chr16:36,613,246...36,695,365

G

eosinophil-associated, ribonuclease A family, member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EAR2 mRNA

NCBI chr14:44,340,111...44,340,988
Ensembl chr14:44,340,111...44,340,991

G

endothelin 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EDN1 mRNA

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

eukaryotic translation elongation factor 2, pseudogene 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EEF2-PS2 mRNA

NCBI chr 4:142,968,397...142,969,938
Ensembl chr 4:142,968,594...142,969,938

G

ephrin A3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EFNA3 mRNA

NCBI chr 3:89,221,200...89,231,359
Ensembl chr 3:89,221,206...89,230,272

G

early growth response 1

increases expression
multiple interactions

monomethylarsonic acid results in increased expression of EGR1 mRNA
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of EGR1 mRNA

PMID:15345372 PMID:23192986

NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037

G

early growth response 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EGR3 mRNA

NCBI chr14:70,314,766...70,320,062
Ensembl chr14:70,314,652...70,320,063

G

leucine rich repeat and fibronectin type III, extracellular 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ELFN2 mRNA

NCBI chr15:78,551,531...78,603,056
Ensembl chr15:78,551,531...78,602,971

G

endonuclease, polyU-specific

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ENDOU mRNA

NCBI chr15:97,608,896...97,629,286
Ensembl chr15:97,608,896...97,629,220

G

eomesodermin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of EOMES mRNA

NCBI chr 9:118,307,259...118,315,176
Ensembl chr 9:118,307,280...118,315,200

G

epilepsy, progressive myoclonic epilepsy, type 2 gene alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EPM2A mRNA

NCBI chr10:11,218,435...11,335,408
Ensembl chr10:11,219,148...11,335,388

G

epiregulin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of EREG mRNA

NCBI chr 5:91,222,476...91,241,508
Ensembl chr 5:91,222,481...91,241,505

G

estrogen receptor 1 (alpha)

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of ESR1 mRNA

NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614

G

ethanolamine kinase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ETNK2 mRNA

NCBI chr 1:133,291,308...133,308,056
Ensembl chr 1:133,291,310...133,308,074

G

E26 avian leukemia oncogene 1, 5' domain

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ETS1 mRNA

NCBI chr 9:32,547,501...32,669,116
Ensembl chr 9:32,547,517...32,669,116

G

exophilin 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of EXPH5 mRNA

NCBI chr 9:53,212,814...53,292,466
Ensembl chr 9:53,212,970...53,288,814

G

fatty acid binding protein 1, liver

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FABP1 mRNA

NCBI chr 6:71,176,863...71,182,018
Ensembl chr 6:71,176,811...71,182,007

G

fatty acid binding protein 3, muscle and heart

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FABP3 mRNA

NCBI chr 4:130,202,531...130,209,256
Ensembl chr 4:130,202,388...130,209,256

G

family with sequence simliarity 151, member A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FAM151A mRNA

NCBI chr 4:106,591,112...106,605,489
Ensembl chr 4:106,591,086...106,605,489

G

family with sequence similarity 161, member B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FAM161B mRNA

NCBI chr12:84,392,088...84,408,633
Ensembl chr12:84,392,083...84,408,607

G

family with sequence similarity 169, member B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FAM169B mRNA

NCBI chr 7:67,923,587...68,012,837
Ensembl chr 7:67,923,587...68,012,840

G

family with sequence similarity 89, member A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FAM89A mRNA

NCBI chr 8:125,466,996...125,478,605
Ensembl chr 8:125,466,996...125,478,571

G

Fanconi anemia, complementation group D2

multiple interactions

[monomethylarsonic acid results in decreased activity of FANCD2 protein] which results in increased susceptibility to diepoxybutane; [monomethylarsonic acid results in decreased activity of FANCD2 protein] which results in increased susceptibility to Hydroxyurea; [monomethylarsonic acid results in decreased activity of FANCD2 protein] which results in increased susceptibility to Mitomycin

NCBI chr 6:113,508,622...113,573,981
Ensembl chr 6:113,508,643...113,573,978

G

Fas cell surface death receptor

decreases expression

monomethylarsonic acid results in decreased expression of FAS mRNA

NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172

G

Fas ligand

increases expression

monomethylarsonic acid results in increased expression of FASLG mRNA

NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064

G

fructose bisphosphatase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FBP1 mRNA

NCBI chr13:63,012,567...63,036,112
Ensembl chr13:63,012,567...63,036,096

G

F-box and leucine-rich repeat protein 22

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FBXL22 mRNA

NCBI chr 9:66,415,738...66,425,752
Ensembl chr 9:66,415,657...66,421,891

G

F-box protein 24

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FBXO24 mRNA

NCBI chr 5:137,610,767...137,623,340
Ensembl chr 5:137,610,765...137,627,264

G

Fc receptor, IgE, low affinity II, alpha polypeptide

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FCER2A mRNA

NCBI chr 8:3,730,280...3,744,174
Ensembl chr 8:3,731,737...3,744,175

G

Fc receptor-like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FCRL1 mRNA

NCBI chr 3:87,283,656...87,311,274
Ensembl chr 3:87,283,694...87,310,241

G

Fc receptor-like A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FCRLA mRNA

NCBI chr 1:170,745,163...170,755,169
Ensembl chr 1:170,745,145...170,755,152

G

farnesyl diphosphate farnesyl transferase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FDFT1 mRNA

NCBI chr14:63,382,599...63,419,136
Ensembl chr14:63,382,599...63,417,027

G

farnesyl diphosphate synthetase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FDPS mRNA

NCBI chr 3:89,000,895...89,009,274
Ensembl chr 3:89,000,895...89,009,266

G

fer-1 like family member 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FER1L5 mRNA

NCBI chr 1:36,411,264...36,461,191
Ensembl chr 1:36,411,372...36,461,191

G

free fatty acid receptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FFAR1 mRNA

NCBI chr 7:30,559,993...30,560,895
Ensembl chr 7:30,556,815...30,560,989

G

fibroblast growth factor 11

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FGF11 mRNA

NCBI chr11:69,686,894...69,693,775
Ensembl chr11:69,686,894...69,692,683

G

fibroblast growth factor 2

increases expression

monomethylarsonic acid results in increased expression of FGF2 mRNA

NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257

G

fibroblast growth factor binding protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FGFBP3 mRNA

NCBI chr19:36,894,950...36,896,999
Ensembl chr19:36,894,950...36,897,015

G

FGR proto-oncogene, Src family tyrosine kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FGR mRNA

NCBI chr 4:132,701,406...132,729,204
Ensembl chr 4:132,701,406...132,729,221

G

FK506 binding protein 5

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of FKBP5 mRNA

NCBI chr17:28,617,727...28,705,123
Ensembl chr17:28,618,068...28,736,501

G

flagellum associated containing coiled-coil domains 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLACC1 mRNA

NCBI chr 1:58,696,085...58,735,167
Ensembl chr 1:58,686,062...58,735,148

G

Friend leukemia integration 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLI1 mRNA

NCBI chr 9:32,333,500...32,454,292
Ensembl chr 9:32,333,500...32,454,157

G

filamin C, gamma

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLNC mRNA

NCBI chr 6:29,433,150...29,461,888
Ensembl chr 6:29,433,255...29,461,882

G

FMS-like tyrosine kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLT3 mRNA

NCBI chr 5:147,267,551...147,337,299
Ensembl chr 5:147,267,551...147,337,299

G

fibronectin type III domain containing 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FNDC10 mRNA

NCBI chr 4:155,778,775...155,780,942
Ensembl chr 4:155,778,799...155,780,938

G

FBJ osteosarcoma oncogene

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of FOS mRNA
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FOS mRNA

PMID:23192986 PMID:34876320

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

formyl peptide receptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FPR1 mRNA

NCBI chr17:18,096,733...18,104,201
Ensembl chr17:18,096,733...18,104,202

G

fascin actin-bundling protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FSCN1 mRNA

NCBI chr 5:142,946,110...142,958,944
Ensembl chr 5:142,946,098...142,958,940

G

fucosyltransferase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FUT1 mRNA

NCBI chr 7:45,266,862...45,270,483
Ensembl chr 7:45,266,713...45,270,483

G

growth arrest and DNA-damage-inducible 45 alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GADD45A mRNA

NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441

G

guanylate binding protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GBP4 mRNA

NCBI chr 3:142,265,781...142,278,974
Ensembl chr 3:142,265,787...142,278,970

G

guanylate-binding protein 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GBP9 mRNA

NCBI chr 5:105,224,331...105,258,255
Ensembl chr 5:105,225,496...105,287,405

G

GTP cyclohydrolase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GCH1 mRNA

NCBI chr14:47,391,352...47,426,870
Ensembl chr14:47,391,352...47,426,870

G

germinal center associated, signaling and motility

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GCSAM mRNA

NCBI chr16:45,430,803...45,443,230
Ensembl chr16:45,430,743...45,443,230

G

growth differentiation factor 15

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GDF15 mRNA

NCBI chr 8:71,082,043...71,085,106
Ensembl chr 8:71,082,043...71,085,106

G

GTPase, IMAP family member 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GIMAP5 mRNA

NCBI chr 6:48,723,131...48,731,134
Ensembl chr 6:48,723,131...48,731,144

G

GTPase, IMAP family member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GIMAP6 mRNA

NCBI chr 6:48,678,517...48,685,178
Ensembl chr 6:48,678,516...48,685,159

G

GTPase, IMAP family member 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GIMAP8 mRNA

NCBI chr 6:48,624,120...48,637,809
Ensembl chr 6:48,624,168...48,637,809

G

gap junction protein, beta 1

increases expression

monomethylarsonic acid results in increased expression of GJB1 mRNA

NCBI chr X:100,419,982...100,429,235
Ensembl chr X:100,419,984...100,429,235

G

GLI-Kruppel family member GLI1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GLI1 mRNA

NCBI chr10:127,165,751...127,177,448
Ensembl chr10:127,165,751...127,177,843

G

glycine receptor, beta subunit

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GLRB mRNA

NCBI chr 3:80,750,905...80,820,994
Ensembl chr 3:80,750,906...80,820,967

G

guanine nucleotide binding protein, alpha 15

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GNA15 mRNA

NCBI chr10:81,338,147...81,360,283
Ensembl chr10:81,338,140...81,360,059

G

G protein subunit alpha transducin 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GNAT1 mRNA

NCBI chr 9:107,551,636...107,556,833
Ensembl chr 9:107,551,673...107,556,911

G

G protein-coupled receptor 132

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR132 mRNA

NCBI chr12:112,814,493...112,832,035
Ensembl chr12:112,814,493...112,831,848

G

G protein-coupled receptor 157

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR157 mRNA

NCBI chr 4:150,171,960...150,190,457
Ensembl chr 4:150,171,822...150,190,384

G

G protein-coupled receptor 17

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GPR17 mRNA

NCBI chr18:32,076,052...32,082,925
Ensembl chr18:32,076,050...32,082,689

G

G protein-coupled receptor 174

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR174 mRNA

NCBI chr X:106,299,484...106,340,377
Ensembl chr X:106,299,484...106,340,375

G

G protein-coupled receptor 179

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR179 mRNA

NCBI chr11:97,222,935...97,243,182
Ensembl chr11:97,222,935...97,242,903

G

G protein-coupled receptor 18

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR18 mRNA

NCBI chr14:122,148,846...122,153,300
Ensembl chr14:122,148,665...122,153,193

G

G protein-coupled receptor 183

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR183 mRNA

NCBI chr14:122,189,743...122,202,605
Ensembl chr14:122,189,963...122,202,607

G

G protein-coupled receptor 34

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR34 mRNA

NCBI chr X:13,489,777...13,507,098
Ensembl chr X:13,498,328...13,507,097

G

glutathione peroxidase 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GPX7 mRNA

NCBI chr 4:108,257,414...108,263,910
Ensembl chr 4:108,257,587...108,264,158

G

GRAM domain containing 2A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GRAMD2A mRNA

NCBI chr 9:59,587,116...59,626,156
Ensembl chr 9:59,587,427...59,626,157

G

GRB2-related adaptor protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GRAP mRNA

NCBI chr11:61,544,081...61,563,610
Ensembl chr11:61,544,091...61,563,610

G

glutathione S-transferase, alpha 2 (Yc2)

decreases expression
increases expression

monomethylarsonic acid results in decreased expression of GSTA2 mRNA; monomethylarsonic acid results in decreased expression of GSTA2 protein
monomethylarsonic acid results in increased expression of GSTA2 mRNA

PMID:16436460 PMID:17481689

NCBI chr 9:78,238,300...78,254,474
Ensembl chr 9:78,238,300...78,263,070

G

glutathione S-transferase alpha 5

increases expression

monomethylarsonic acid results in increased expression of GSTA2 mRNA

NCBI chr 9:78,197,210...78,212,807
Ensembl chr 9:78,197,205...78,212,807

G

glutathione S-transferase, mu 1

increases expression

monomethylarsonic acid results in increased expression of GSTM1 mRNA; monomethylarsonic acid results in increased expression of GSTM1 protein

NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289

G

glutathione S-transferase omega 1

increases reduction
multiple interactions

GSTO1 protein results in increased reduction of monomethylarsonic acid
[GSTO1 protein results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of monomethylarsonous acid

PMID:12928150 PMID:15929903

NCBI chr19:47,843,412...47,853,229
Ensembl chr19:47,843,409...47,853,229

G

glutathione S-transferase, pi 1

increases expression

monomethylarsonic acid results in increased expression of GSTP1 mRNA

NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985

G

glutathione S-transferase, theta 1

affects methylation
multiple interactions

GSTT1 protein affects the methylation of monomethylarsonic acid
[GSTT1 gene polymorphism affects the metabolism of Arsenic] which affects the abundance of monomethylarsonic acid

PMID:17431481 PMID:32650499

NCBI chr10:75,619,647...75,634,418
Ensembl chr10:75,619,647...75,634,418

G

guanylate cyclase activator 1B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GUCA1B mRNA

NCBI chr17:47,692,526...47,703,892
Ensembl chr17:47,696,318...47,703,892

G

granzyme A

decreases expression

monomethylarsonic acid results in decreased expression of GZMA mRNA

NCBI chr13:113,230,358...113,237,515
Ensembl chr13:113,230,359...113,237,515

G

granzyme K

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GZMK mRNA

NCBI chr13:113,308,164...113,317,499
Ensembl chr13:113,308,142...113,362,442

G

histocompatibility 2, class II, locus Mb2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of H2-DMB2 mRNA

NCBI chr17:34,362,203...34,370,527
Ensembl chr17:34,362,281...34,370,529

G

histocompatibility 2, class II antigen E beta2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of H2-EB2 mRNA

NCBI chr17:34,544,477...34,560,384
Ensembl chr17:34,544,639...34,560,386

G

histocompatibility 2, M region locus 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of H2-M2 mRNA

NCBI chr17:37,791,742...37,794,445
Ensembl chr17:37,791,742...37,794,443

G

histocompatibility 2, O region alpha locus

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of H2-OA mRNA

NCBI chr17:34,311,353...34,314,286
Ensembl chr17:34,311,314...34,314,208

G

histocompatibility 2, O region beta locus

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of H2-OB mRNA

NCBI chr17:34,457,879...34,464,882
Ensembl chr17:34,457,877...34,473,388

G

histocompatibility 2, Q region locus 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of H2-Q3 mRNA

NCBI chr17:35,577,945...35,578,958
Ensembl chr17:35,577,965...35,578,948

G

H4 clustered histone 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of H4C14 mRNA

NCBI chr13:23,940,920...23,941,369
Ensembl chr13:23,940,996...23,941,392

G

3-hydroxyanthranilate 3,4-dioxygenase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HAAO mRNA

NCBI chr17:84,138,777...84,157,589
Ensembl chr17:84,138,585...84,155,392

G

hematopoietic cell specific Lyn substrate 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HCLS1 mRNA

NCBI chr16:36,755,345...36,783,576
Ensembl chr16:36,755,345...36,783,574

G

hyperpolarization-activated, cyclic nucleotide-gated K+ 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HCN2 mRNA

NCBI chr10:79,552,468...79,571,942
Ensembl chr10:79,552,468...79,571,942

G

histidine decarboxylase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HDC mRNA

NCBI chr 2:126,435,579...126,465,942
Ensembl chr 2:126,435,587...126,461,219

G

hedgehog acyltransferase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HHAT mRNA

NCBI chr 1:192,195,133...192,453,546
Ensembl chr 1:192,179,019...192,453,531

G

hematopoietically expressed homeobox

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HHEX mRNA

NCBI chr19:37,423,289...37,429,179
Ensembl chr19:37,423,258...37,429,179

G

hexokinase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HK2 mRNA

NCBI chr 6:82,702,004...82,751,437
Ensembl chr 6:82,702,006...82,751,435

G

high mobility group box 1, pseudogene 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HMGB1-PS8 mRNA

Ensembl chr10:22,138,641...22,139,266

G

3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HMGCS1 mRNA

NCBI chr13:120,151,887...120,169,796
Ensembl chr13:120,151,915...120,169,796

G

3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HMGCS2 mRNA

NCBI chr 3:98,187,747...98,218,054
Ensembl chr 3:98,187,751...98,218,054

G

heme oxygenase 1

increases expression
decreases expression
multiple interactions

monomethylarsonic acid results in increased expression of HMOX1 mRNA
monomethylarsonic acid results in decreased expression of HMOX1 mRNA
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of HMOX1 mRNA

PMID:15345372 PMID:23192986 PMID:24091636

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

HNF1 homeobox A, opposite strand 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HNF1AOS1 mRNA

NCBI chr 5:115,106,802...115,135,985
Ensembl chr 5:115,106,843...115,136,105

G

4-hydroxy-2-oxoglutarate aldolase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HOGA1 mRNA

NCBI chr19:42,033,998...42,060,128
Ensembl chr19:42,034,049...42,059,392

G

homeobox D3, opposite strand 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HOXD3OS1 mRNA

NCBI chr 2:74,540,388...74,546,474
Ensembl chr 2:74,533,592...74,546,474

G

hippocalcin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HPCA mRNA

NCBI chr 4:129,005,363...129,019,712
Ensembl chr 4:129,005,363...129,015,829

G

heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HS3ST3B1 mRNA

NCBI chr11:63,775,519...63,813,110
Ensembl chr11:63,776,618...63,813,116

G

heat shock transcription factor 2 binding protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HSF2BP mRNA

NCBI chr17:32,163,743...32,253,869
Ensembl chr17:32,163,743...32,255,323

G

heat shock protein 1A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPA1A mRNA

NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132

G

heat shock protein 1B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPA1B mRNA

NCBI chr17:35,175,405...35,178,214
Ensembl chr17:35,175,412...35,178,214

G

heat shock protein 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPA8 mRNA

NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383

G

heat shock protein family, member 7 (cardiovascular)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HSPB7 mRNA

NCBI chr 4:141,148,090...141,152,621
Ensembl chr 4:141,148,090...141,152,622

G

heat shock 105kDa/110kDa protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPH1 mRNA

NCBI chr 5:149,540,308...149,562,594
Ensembl chr 5:149,537,752...149,559,841

G

hydrogen voltage-gated channel 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HVCN1 mRNA

NCBI chr 5:122,344,872...122,380,360
Ensembl chr 5:122,344,867...122,380,360

G

intercellular adhesion molecule 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ICAM1 mRNA

NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113

G

inducible T cell co-stimulator

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ICOS mRNA

NCBI chr 1:60,999,909...61,039,481
Ensembl chr 1:61,017,086...61,039,479

G

interferon activated gene 203

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IFI203 mRNA

NCBI chr 1:173,747,966...173,770,432
Ensembl chr 1:173,747,973...173,770,238

G

interferon activated gene 206

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IFI206 mRNA

NCBI chr 1:173,296,051...173,318,884
Ensembl chr 1:173,296,051...173,318,607

G

interferon activated gene 208

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IFI208 mRNA

NCBI chr 1:173,501,194...173,525,959
Ensembl chr 1:173,501,241...173,525,961

G

interferon activated gene 209

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IFI209 mRNA

NCBI chr 1:173,458,425...173,475,494
Ensembl chr 1:173,458,483...173,475,494

G

interferon activated gene 213

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IFI213 mRNA

NCBI chr 1:173,393,849...173,426,868
Ensembl chr 1:173,393,849...173,426,840

G

interferon activated gene 214

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IFI214 mRNA

NCBI chr 1:173,348,877...173,363,523
Ensembl chr 1:173,347,283...173,363,523

G

insulin-like growth factor I receptor

increases expression

monomethylarsonic acid results in increased expression of IGF1R mRNA

NCBI chr 7:67,601,486...67,883,416
Ensembl chr 7:67,602,575...67,883,416

G

insulin-like growth factor binding protein 1

increases expression

monomethylarsonic acid results in increased expression of IGFBP1 mRNA

NCBI chr11:7,147,787...7,152,546
Ensembl chr11:7,147,782...7,152,546

G

immunoglobulin heavy constant alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHA mRNA

NCBI chr12:113,219,824...113,223,856
Ensembl chr12:113,218,450...113,223,856

G

immunoglobulin heavy constant delta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHD mRNA

NCBI chr12:113,371,155...113,379,944
Ensembl chr12:113,370,224...113,379,944

G

immunoglobulin heavy constant gamma 2B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHG2B mRNA

NCBI chr12:113,267,934...113,271,553
Ensembl chr12:113,266,585...113,271,553

G

immunoglobulin heavy constant gamma 2C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHG2C mRNA

NCBI chr12:113,251,009...113,252,552
Ensembl chr12:113,248,945...113,252,552

G

immunoglobulin heavy constant mu

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHM mRNA

NCBI chr12:113,382,446...113,386,350
Ensembl chr12:113,382,178...113,386,350

G

immunoglobulin heavy variable V1-18

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV1-18 mRNA

NCBI chr12:114,646,252...114,646,545
Ensembl chr12:114,646,252...114,646,685

G

immunoglobulin heavy variable 1-26

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV1-26 mRNA

NCBI chr12:114,751,992...114,752,285
Ensembl chr12:114,751,992...114,752,425

G

immunoglobulin heavy variable 1-39

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV1-39 mRNA

NCBI chr12:114,878,219...114,878,512
Ensembl chr12:114,878,219...114,878,652

G

immunoglobulin heavy variable V1-54

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV1-54 mRNA

NCBI chr12:115,157,295...115,157,588
Ensembl chr12:115,157,295...115,157,754

G

immunoglobulin heavy variable 1-58

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of IGHV1-58 mRNA

NCBI chr12:115,275,786...115,276,217
Ensembl chr12:115,275,786...115,276,219

G

immunoglobulin heavy variable V1-59

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV1-59 mRNA

NCBI chr12:115,298,677...115,299,133
Ensembl chr12:115,298,702...115,299,134

G

immunoglobulin heavy variable 1-64

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV1-64 mRNA

NCBI chr12:115,471,207...115,471,597
Ensembl chr12:115,471,165...115,471,651

G

immunoglobulin heavy variable 1-72

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV1-72 mRNA

NCBI chr12:115,721,604...115,721,897
Ensembl chr12:115,721,604...115,722,081

G

immunoglobulin heavy variable 1-75

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV1-75 mRNA

NCBI chr12:115,797,570...115,797,863
Ensembl chr12:115,797,570...115,798,038

G

immunoglobulin heavy variable 1-78

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of IGHV1-78 mRNA

NCBI chr12:115,832,393...115,832,686
Ensembl chr12:115,832,393...115,832,847

G

immunoglobulin heavy variable 1-80

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV1-80 mRNA

NCBI chr12:115,875,964...115,876,257
Ensembl chr12:115,875,964...115,876,396

G

immunoglobulin heavy variable 1-81

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of IGHV1-81 mRNA

NCBI chr12:115,883,899...115,884,192
Ensembl chr12:115,883,899...115,884,332

G

immunoglobulin heavy variable 10-1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV10-1 mRNA

NCBI chr12:114,442,627...114,443,071
Ensembl chr12:114,442,625...114,443,071

G

immunoglobulin heavy variable 2-9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV2-9 mRNA

NCBI chr12:113,842,717...113,843,008
Ensembl chr12:113,842,716...113,843,161

G

immunoglobulin heavy variable 3-5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of IGHV3-5 mRNA

NCBI chr12:114,226,272...114,226,570
Ensembl chr12:114,226,272...114,226,707

G

immunoglobulin heavy variable V3-8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV3-8 mRNA

NCBI chr12:114,285,996...114,286,286
Ensembl chr12:114,285,947...114,286,421

G

immunoglobulin heavy variable 4-1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of IGHV4-1 mRNA

NCBI chr12:113,911,904...113,912,197
Ensembl chr12:113,911,902...113,912,416

G

immunoglobulin heavy variable 5-17

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV5-17 mRNA

NCBI chr12:113,822,769...113,823,062
Ensembl chr12:113,822,769...113,823,290

G

immunoglobulin heavy variable 5-9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV5-9 mRNA

NCBI chr12:113,625,391...113,625,848
Ensembl chr12:113,625,389...113,625,913

G

immunoglobulin heavy variable 5-9-1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV5-9-1 mRNA

NCBI chr12:113,699,733...113,700,026
Ensembl chr12:113,699,731...113,700,250

G

immunoglobulin heavy variable 6-3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of IGHV6-3 mRNA

NCBI chr12:114,355,332...114,355,630
Ensembl chr12:114,355,332...114,355,789

G

immunoglobulin heavy variable 7-3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV7-3 mRNA

NCBI chr12:114,116,800...114,117,264
Ensembl chr12:114,116,800...114,117,264

G

immunoglobulin heavy variable V8-12

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV8-12 mRNA

NCBI chr12:115,611,565...115,611,865
Ensembl chr12:115,611,565...115,612,007

G

immunoglobulin kappa variable 1-133

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGKV1-133 mRNA

NCBI chr 6:67,701,898...67,702,645
Ensembl chr 6:67,701,886...67,702,645

G

immunoglobulin kappa variable 10-96

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGKV10-96 mRNA

NCBI chr 6:68,608,949...68,609,414
Ensembl chr 6:68,608,947...68,609,426

G

immunoglobulin kappa variable 2-109

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGKV2-109 mRNA

NCBI chr 6:68,279,423...68,280,142
Ensembl chr 6:68,279,411...68,280,142

G

immunoglobulin kappa variable 4-53

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGKV4-53 mRNA

NCBI chr 6:69,625,808...69,626,338
Ensembl chr 6:69,625,808...69,626,347

G

immunoglobulin kappa variable 4-68

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGKV4-68 mRNA

NCBI chr 6:69,281,818...69,282,347
Ensembl chr 6:69,281,818...69,282,389

G

immunoglobulin kappa variable 4-69

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGKV4-69 mRNA

NCBI chr 6:69,260,778...69,261,303
Ensembl chr 6:69,260,778...69,261,303

G

immunoglobulin kappa chain variable 4-91

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGKV4-91 mRNA

NCBI chr 6:68,745,539...68,746,087
Ensembl chr 6:68,745,539...68,746,087

G

immunoglobulin kappa variable 6-13

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGKV6-13 mRNA

NCBI chr 6:70,434,487...70,435,020
Ensembl chr 6:70,434,485...70,435,020

G

immunoglobulin kappa variable 6-14

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of IGKV6-14 mRNA

NCBI chr 6:70,411,936...70,412,460
Ensembl chr 6:70,411,936...70,412,460

G

immunoglobulin kappa variable 6-17

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGKV6-17 mRNA

NCBI chr 6:70,348,453...70,348,977
Ensembl chr 6:70,348,423...70,348,977

G

immunoglobulin kappa variable 6-20

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGKV6-20 mRNA

NCBI chr 6:70,312,825...70,313,463
Ensembl chr 6:70,312,825...70,313,491

G

immunoglobulin lambda constant 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGLC2 mRNA

NCBI chr16:19,017,286...19,017,602
Ensembl chr16:19,017,146...19,019,101

G

IKAROS family zinc finger 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IKZF1 mRNA

NCBI chr11:11,634,970...11,722,930
Ensembl chr11:11,634,980...11,722,926

G

interleukin 10 receptor, alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL10RA mRNA

NCBI chr 9:45,165,135...45,180,447
Ensembl chr 9:45,165,135...45,180,447

G

interleukin 13 receptor, alpha 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL13RA2 mRNA

NCBI chr X:146,166,474...146,214,982
Ensembl chr X:146,166,472...146,212,188

G

interleukin 20 receptor beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL20RB mRNA

NCBI chr 9:100,339,772...100,368,526
Ensembl chr 9:100,339,772...100,368,841

G

interleukin 21 receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL21R mRNA

NCBI chr 7:125,202,424...125,232,742
Ensembl chr 7:125,202,601...125,232,742

G

interleukin 22 receptor, alpha 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL22RA2 mRNA

NCBI chr10:19,497,776...19,510,429
Ensembl chr10:19,497,746...19,510,429

G

interleukin 27 receptor, alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL27RA mRNA

NCBI chr 8:84,756,915...84,769,250
Ensembl chr 8:84,756,923...84,769,218

G

interleukin 36B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL36B mRNA

NCBI chr 2:24,043,184...24,050,115
Ensembl chr 2:24,043,173...24,050,531

G

interleukin 5 receptor, alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL5RA mRNA

NCBI chr 6:106,687,336...106,725,998
Ensembl chr 6:106,687,318...106,725,998

G

interleukin 7 receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL7R mRNA

NCBI chr15:9,505,880...9,530,270
Ensembl chr15:9,505,874...9,530,262

G

interleukin 9 receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL9R mRNA

NCBI chr11:32,137,544...32,155,283
Ensembl chr11:32,137,541...32,150,279

G

insulin I

multiple interactions

monomethylarsonic acid inhibits the reaction [INS1 protein results in increased uptake of Glucose]

NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914

G

insulin induced gene 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of INSIG1 mRNA

NCBI chr 5:28,276,410...28,283,660
Ensembl chr 5:28,276,361...28,283,660

G

interferon regulatory factor 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IRF4 mRNA

NCBI chr13:30,933,191...30,950,965
Ensembl chr13:30,933,209...30,950,959

G

integrin, alpha 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ITGA10 mRNA

NCBI chr 3:96,552,900...96,571,835
Ensembl chr 3:96,552,900...96,571,835

G

integrin alpha 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITGA8 mRNA

NCBI chr 2:12,111,443...12,306,755
Ensembl chr 2:12,111,443...12,306,733

G

integrin alpha L

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITGAL mRNA

NCBI chr 7:126,895,404...126,934,309
Ensembl chr 7:126,895,432...126,934,310

G

integrin beta 2-like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ITGB2L mRNA

NCBI chr16:96,223,488...96,244,861
Ensembl chr16:96,223,488...96,244,819

G

integrin beta 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITGB8 mRNA

NCBI chr12:119,121,757...119,202,891
Ensembl chr12:119,121,757...119,202,537

G

inter-alpha trypsin inhibitor, heavy chain 3

increases expression

monomethylarsonic acid results in increased expression of ITIH3 mRNA

NCBI chr14:30,630,529...30,645,748
Ensembl chr14:30,630,529...30,645,717

G

inositol 1,4,5-triphosphate receptor interacting protein-like 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITPRIPL2 mRNA

NCBI chr 7:118,084,334...118,091,198
Ensembl chr 7:118,084,334...118,091,198

G

IZUMO1 receptor, JUNO

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IZUMO1R mRNA

NCBI chr 9:14,797,110...14,815,247
Ensembl chr 9:14,797,110...14,815,245

G

jun proto-oncogene

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of JUN mRNA

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

G

potassium voltage-gated channel, subfamily G, member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KCNG1 mRNA

NCBI chr 2:168,102,037...168,123,453
Ensembl chr 2:168,102,037...168,123,656

G

Kv channel interacting protein 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KCNIP4 mRNA

NCBI chr 5:48,546,845...49,682,464
Ensembl chr 5:48,546,844...49,682,249

G

potassium inwardly-rectifying channel, subfamily J, member 13

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of KCNJ13 mRNA

NCBI chr 1:87,312,299...87,322,451
Ensembl chr 1:87,314,085...87,322,451

G

potassium inwardly-rectifying channel, subfamily K, member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of KCNK6 mRNA

NCBI chr 7:28,921,353...28,931,947
Ensembl chr 7:28,921,351...28,931,940

G

kelch-like 30

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KLHL30 mRNA

NCBI chr 1:91,278,795...91,290,126
Ensembl chr 1:91,278,738...91,290,138

G

kelch-like 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KLHL6 mRNA

NCBI chr16:19,765,242...19,801,766
Ensembl chr16:19,765,246...19,801,787

G

killer cell lectin-like receptor subfamily B member 1A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KLRB1 mRNA

NCBI chr 6:128,586,190...128,599,897
Ensembl chr 6:128,586,190...128,600,496

G

kynurenine 3-monooxygenase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KMO mRNA

NCBI chr 1:175,459,759...175,488,419
Ensembl chr 1:175,447,947...175,489,682

G

keratin 12

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KRT12 mRNA

NCBI chr11:99,306,490...99,313,419
Ensembl chr11:99,306,492...99,313,085

G

keratin 17

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KRT17 mRNA

NCBI chr11:100,147,041...100,151,855
Ensembl chr11:100,147,043...100,151,855

G

keratin 18

decreases expression

monomethylarsonic acid results in decreased expression of KRT18 mRNA

NCBI chr15:101,936,651...101,940,461
Ensembl chr15:101,936,615...101,940,462

G

keratin 27

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KRT27 mRNA

NCBI chr11:99,236,391...99,241,944
Ensembl chr11:99,236,391...99,241,930

G

L3MBTL3 histone methyl-lysine binding protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of L3MBTL3 mRNA

NCBI chr10:26,150,361...26,252,426
Ensembl chr10:26,150,366...26,251,967

G

ladinin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LAD1 mRNA

NCBI chr 1:135,746,336...135,761,079
Ensembl chr 1:135,746,336...135,761,080

G

leucyl-tRNA synthetase, mitochondrial

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LARS2 mRNA

NCBI chr 9:123,196,001...123,291,731
Ensembl chr 9:123,195,992...123,291,731

G

lymphocyte transmembrane adaptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LAX1 mRNA

NCBI chr 1:133,606,767...133,620,760
Ensembl chr 1:133,606,829...133,617,846

G

lymphocyte cytosolic protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LCP1 mRNA

NCBI chr14:75,368,570...75,468,282
Ensembl chr14:75,368,541...75,468,282

G

low density lipoprotein receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LDLR mRNA

NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215

G

lymphoid enhancer binding factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LEF1 mRNA

NCBI chr 3:130,903,972...131,018,006
Ensembl chr 3:130,904,120...131,018,005

G

lectin, galactose-binding, soluble 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LGALS2 mRNA

NCBI chr15:78,735,060...78,739,729
Ensembl chr15:78,735,060...78,739,729

G

lectin, galactose binding, soluble 8

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of LGALS8 mRNA

NCBI chr13:12,454,283...12,479,857
Ensembl chr13:12,454,296...12,479,825

G

lipoma HMGIC fusion partner-like 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of LHFPL2 mRNA

NCBI chr13:94,193,659...94,331,918
Ensembl chr13:94,194,304...94,331,917

G

lipase, hepatic

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LIPC mRNA

NCBI chr 9:70,705,410...70,859,503
Ensembl chr 9:70,705,410...70,859,508

G

lysophosphatidylcholine acyltransferase 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of LPCAT4 mRNA

NCBI chr 2:112,070,186...112,077,456
Ensembl chr 2:112,069,813...112,077,456

G

leupaxin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LPXN mRNA

NCBI chr19:12,773,251...12,811,177
Ensembl chr19:12,773,557...12,811,171

G

leucine rich repeat containing 31

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LRRC31 mRNA

NCBI chr 3:30,732,703...30,753,992
Ensembl chr 3:30,732,703...30,753,992

G

leucine-rich repeat kinase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LRRK2 mRNA

NCBI chr15:91,556,994...91,700,327
Ensembl chr15:91,557,378...91,700,323

G

lanosterol synthase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LSS mRNA

NCBI chr10:76,367,303...76,392,973
Ensembl chr10:76,367,422...76,392,972

G

lymphotoxin A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LTA mRNA

NCBI chr17:35,422,141...35,424,568
Ensembl chr17:35,422,141...35,424,327

G

lymphotoxin B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LTB mRNA

NCBI chr17:35,413,483...35,415,281
Ensembl chr17:35,413,415...35,415,296

G

leukotriene B4 receptor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LTB4R2 mRNA

NCBI chr14:55,995,379...56,001,523
Ensembl chr14:55,998,885...56,002,595

G

lymphocyte antigen 6 family member D

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LY6D mRNA

NCBI chr15:74,633,905...74,635,416
Ensembl chr15:74,633,905...74,635,469

G

lymphocyte antigen 6 family member G

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LY6G mRNA

NCBI chr15:75,027,110...75,030,977
Ensembl chr15:75,027,089...75,030,975

G

lymphocyte antigen 6 family member G6C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of LY6G6C mRNA

NCBI chr17:35,286,301...35,289,024
Ensembl chr17:35,284,364...35,289,026

G

lymphocyte antigen 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LY9 mRNA

NCBI chr 1:171,416,172...171,434,917
Ensembl chr 1:171,416,192...171,434,978

G

lymphoblastomic leukemia 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LYL1 mRNA

NCBI chr 8:85,428,051...85,432,876
Ensembl chr 8:85,428,078...85,431,569

G

lysozyme 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LYZ1 mRNA

NCBI chr10:117,123,700...117,128,773
Ensembl chr10:117,123,702...117,128,773

G

mitogen-activated protein kinase kinase kinase 19

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MAP3K19 mRNA

NCBI chr 1:127,741,217...127,782,763
Ensembl chr 1:127,742,528...127,782,768

G

mitogen-activated protein kinase kinase kinase 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MAP3K9 mRNA

NCBI chr12:81,761,724...81,828,010
Ensembl chr12:81,767,784...81,827,949

G

mitogen-activated protein kinase kinase kinase kinase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MAP4K1 mRNA

NCBI chr 7:28,681,506...28,702,704
Ensembl chr 7:28,681,475...28,702,704

G

mitogen-activated protein kinase 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MAPK1 mRNA

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 15

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MAPK15 mRNA

NCBI chr15:75,865,581...75,871,002
Ensembl chr15:75,865,618...75,871,003

G

melanin-concentrating hormone receptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MCHR1 mRNA

NCBI chr15:81,119,700...81,123,165
Ensembl chr15:81,119,700...81,123,165

G

mast cell protease 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MCPT1 mRNA

NCBI chr14:56,255,421...56,257,848
Ensembl chr14:56,255,428...56,257,841

G

mast cell protease 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MCPT2 mRNA

NCBI chr14:56,259,041...56,282,092
Ensembl chr14:56,279,498...56,282,099

G

transformed mouse 3T3 cell double minute 2

increases expression
multiple interactions

monomethylarsonic acid results in increased expression of MDM2 mRNA
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MDM2 mRNA

PMID:17481689 PMID:23192986

NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663

G

myocyte enhancer factor 2C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MEF2C mRNA

NCBI chr13:83,652,136...83,815,197
Ensembl chr13:83,652,153...83,815,199

G

meiosis specific with coiled-coil domain

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MEIOC mRNA

NCBI chr11:102,556,177...102,573,066
Ensembl chr11:102,554,542...102,573,063

G

macrophage expressed LXRa(NR1H3)-dependent amplifier of Abca1 transcription lncRNA

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MEXIS mRNA

NCBI chr 4:53,261,356...53,270,232
Ensembl chr 4:53,261,356...53,270,232

G

milk fat globule EGF and factor V/VIII domain containing

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MFGE8 mRNA

NCBI chr 7:78,783,516...78,798,808
Ensembl chr 7:78,783,516...78,798,808

G

major facilitator superfamily domain containing 12

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MFSD12 mRNA

NCBI chr10:81,193,325...81,202,059
Ensembl chr10:81,193,325...81,202,059

G

MFSD2 lysolipid transporter B, sphingolipid

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MFSD2B mRNA

NCBI chr12:4,912,438...4,924,359
Ensembl chr12:4,912,440...4,924,359

G

microRNA 145a

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MIR145A mRNA

NCBI chr18:61,780,896...61,780,965
Ensembl chr18:61,780,896...61,780,965

G

Mir155 host gene (non-protein coding)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MIR155HG mRNA

NCBI chr16:84,509,911...84,512,133
Ensembl chr16:84,500,055...84,512,133

G

microRNA 192

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MIR192 mRNA

NCBI chr19:6,314,874...6,314,962
Ensembl chr19:6,314,874...6,314,962

G

mohawk homeobox

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MKX mRNA

NCBI chr18:6,934,966...7,004,779
Ensembl chr18:6,934,518...7,004,780

G

myeloid nuclear differentiation antigen like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MNDAL mRNA

NCBI chr 1:173,684,786...173,708,038
Ensembl chr 1:173,676,692...173,708,447

G

mucosal pentraxin 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MPTX2 mRNA

NCBI chr 1:173,102,028...173,105,323
Ensembl chr 1:173,101,949...173,105,344

G

maestro heat-like repeat family member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MROH6 mRNA

NCBI chr15:75,753,085...75,762,544
Ensembl chr15:75,755,986...75,760,619

G

maestro heat-like repeat family member 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MROH7 mRNA

NCBI chr 4:106,537,614...106,595,059
Ensembl chr 4:106,537,614...106,588,122

G

membrane-spanning 4-domains, subfamily A, member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MS4A1 mRNA

NCBI chr19:11,227,043...11,243,513
Ensembl chr19:11,227,039...11,243,605

G

membrane-spanning 4-domains, subfamily A, member 18

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MS4A18 mRNA

NCBI chr19:10,974,388...10,995,390
Ensembl chr19:10,974,389...10,995,395

G

membrane-spanning 4-domains, subfamily A, member 4B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MS4A4B mRNA

NCBI chr19:11,420,922...11,440,913
Ensembl chr19:11,420,917...11,444,419

G

membrane-spanning 4-domains, subfamily A, member 6B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MS4A6B mRNA

NCBI chr19:11,495,923...11,507,767
Ensembl chr19:11,493,876...11,508,620

G

mutS homolog 2

decreases expression

monomethylarsonic acid results in decreased expression of MSH2 mRNA

NCBI chr17:87,979,960...88,031,141
Ensembl chr17:87,979,758...88,031,141

G

misato 1, mitochondrial distribution and morphology regulator

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MSTO1 mRNA

NCBI chr 3:88,816,923...88,821,257
Ensembl chr 3:88,812,414...88,821,306

G

12S rRNA, mitochondrial

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MT-RNR1 mRNA

NCBI chr MT:70...1,024
Ensembl chr MT:70...1,024

G

16S rRNA, mitochondrial

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MT-RNR2 mRNA

NCBI chr MT:1,094...2,675
Ensembl chr MT:1,094...2,675

G

metallothionein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MT1 mRNA

NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955

G

metallothionein 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MT4 mRNA

NCBI chr 8:94,863,832...94,865,659
Ensembl chr 8:94,863,825...94,865,659

G

mevalonate (diphospho) decarboxylase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MVD mRNA

NCBI chr 8:123,160,335...123,170,161
Ensembl chr 8:123,160,340...123,170,161

G

mevalonate kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MVK mRNA

NCBI chr 5:114,582,324...114,598,652
Ensembl chr 5:114,582,330...114,598,652

G

MX dynamin-like GTPase 1

multiple interactions

[Arsenic results in increased abundance of monomethylarsonic acid] which affects the expression of MX1 mRNA
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MX1 mRNA

PMID:28793237 PMID:34876320

NCBI chr16:97,248,235...97,264,106
Ensembl chr16:97,248,235...97,264,107

G

Max dimerization protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MXD3 mRNA

NCBI chr13:55,472,983...55,477,937
Ensembl chr13:55,472,981...55,477,636

G

myeloblastosis oncogene-like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MYBL1 mRNA

NCBI chr 1:9,737,632...9,770,664
Ensembl chr 1:9,737,640...9,770,434

G

myelocytomatosis oncogene

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MYC mRNA

NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223

G

myosin IG

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MYO1G mRNA

NCBI chr11:6,456,548...6,470,960
Ensembl chr11:6,456,548...6,470,965

G

myotilin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MYOT mRNA

NCBI chr18:44,467,126...44,488,795
Ensembl chr18:44,467,141...44,488,791

G

marginal zone B and B1 cell-specific protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MZB1 mRNA

NCBI chr18:35,780,318...35,782,420
Ensembl chr18:35,780,320...35,782,420

G

N-6 adenine-specific DNA methyltransferase 1 (putative)

increases abundance

N6AMT1 gene polymorphism results in increased abundance of monomethylarsonic acid

NCBI chr16:87,151,073...87,165,537
Ensembl chr16:87,151,073...87,165,630

G

N-acetylated alpha-linked acidic dipeptidase-like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NAALADL1 mRNA

NCBI chr19:6,155,811...6,166,019
Ensembl chr19:6,155,812...6,165,822

G

napsin A aspartic peptidase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NAPSA mRNA

NCBI chr 7:44,221,869...44,236,270
Ensembl chr 7:44,221,804...44,236,286

G

neutrophil cytosolic factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NCF1 mRNA

NCBI chr 5:134,248,907...134,258,479
Ensembl chr 5:134,248,907...134,258,479

G

noncompact myelin associated protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NCMAP mRNA

NCBI chr 4:135,096,887...135,125,551
Ensembl chr 4:135,096,887...135,125,538

G

N-myc downstream regulated gene 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NDRG1 mRNA

NCBI chr15:66,801,167...66,841,490
Ensembl chr15:66,801,167...66,841,489

G

N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NDST3 mRNA

NCBI chr 3:123,319,815...123,484,822
Ensembl chr 3:123,319,815...123,484,502

G

nuclear paraspeckle assembly transcript 1 (non-protein coding)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NEAT1 mRNA

NCBI chr19:5,874,736...5,895,508
Ensembl chr19:5,874,736...5,895,898

G

nebulin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NEB mRNA

NCBI chr 2:52,026,652...52,228,810
Ensembl chr 2:52,026,659...52,268,486

G

nectin cell adhesion molecule 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NECTIN1 mRNA

NCBI chr 9:43,655,251...43,718,758
Ensembl chr 9:43,655,281...43,743,955

G

nuclear factor, erythroid derived 2,-like 1

multiple interactions

[NFE2L1 protein alternative form results in decreased methylation of arsenite] which results in decreased abundance of monomethylarsonic acid

NCBI chr11:96,708,239...96,720,810
Ensembl chr11:96,708,240...96,720,794

G

nuclear factor, erythroid derived 2, like 2

decreases expression
multiple interactions

monomethylarsonic acid results in decreased expression of NFE2L2 mRNA
monomethylarsonic acid results in increased expression of and affects the localization of NFE2L2 protein; NFE2L2 mutant form inhibits the reaction [monomethylarsonic acid results in increased expression of NQO1 protein]

PMID:24091636 PMID:24161444

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear factor, interleukin 3, regulated

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NFIL3 mRNA

NCBI chr13:53,121,245...53,136,914
Ensembl chr13:53,121,245...53,135,109

G

nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of NFKB1 mRNA

NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308

G

niban apoptosis regulator 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NIBAN3 mRNA

NCBI chr 8:72,049,000...72,061,599
Ensembl chr 8:72,050,292...72,060,580

G

NIPA-like domain containing 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NIPAL4 mRNA

NCBI chr11:46,038,982...46,057,186
Ensembl chr11:46,038,982...46,057,335

G

NLR family, pyrin domain containing 9B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NLRP9B mRNA

NCBI chr 7:19,725,318...19,796,867
Ensembl chr 7:19,725,390...19,807,231

G

neuromedin U

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NMU mRNA

NCBI chr 5:76,481,342...76,511,624
Ensembl chr 5:76,481,342...76,511,635

G

nocturnin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NOCT mRNA

NCBI chr 3:51,131,868...51,159,075
Ensembl chr 3:51,131,868...51,159,065

G

neuronal PAS domain protein 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NPAS4 mRNA

NCBI chr19:5,034,381...5,053,467
Ensembl chr19:5,034,383...5,040,344

G

neuropeptide FF receptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NPFFR1 mRNA

NCBI chr10:61,430,600...61,465,243
Ensembl chr10:61,431,271...61,464,344

G

NAD(P)H dehydrogenase, quinone 1

multiple interactions
increases expression

monomethylarsonic acid promotes the reaction [sulforaphane results in increased expression of and results in increased activity of NQO1 protein]; monomethylarsonic acid promotes the reaction [sulforaphane results in increased expression of NQO1 mRNA]; monomethylarsonic acid promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of NQO1 protein]; monomethylarsonic acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]; monomethylarsonic acid results in increased expression of and results in increased activity of NQO1 protein; NFE2L2 mutant form inhibits the reaction [monomethylarsonic acid results in increased expression of NQO1 protein]
monomethylarsonic acid results in increased expression of NQO1 mRNA

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NR0B2 mRNA

NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847

G

5' nucleotidase, ecto

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NT5E mRNA

NCBI chr 9:88,209,662...88,254,142
Ensembl chr 9:88,209,250...88,254,145

G

nuclear GTPase, germinal center associated

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NUGGC mRNA

NCBI chr14:65,830,901...65,885,893
Ensembl chr14:65,835,995...65,885,980

G

neurexophilin and PC-esterase domain family, member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NXPE3 mRNA

NCBI chr16:55,660,316...55,717,467
Ensembl chr16:55,660,316...55,715,648

G

neurexophilin and PC-esterase domain family, member 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NXPE4 mRNA

NCBI chr 9:48,073,302...48,311,325
Ensembl chr 9:48,073,321...48,311,325

G

nyctalopin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NYX mRNA

NCBI chr X:13,327,097...13,359,059
Ensembl chr X:13,332,349...13,355,552

G

2'-5' oligoadenylate synthetase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of OAS2 mRNA

NCBI chr 5:120,868,398...120,887,949
Ensembl chr 5:120,868,398...120,887,918

G

8-oxoguanine DNA-glycosylase 1

increases expression

monomethylarsonic acid results in increased expression of OGG1 mRNA

NCBI chr 6:113,303,959...113,311,149
Ensembl chr 6:113,303,933...113,312,029

G

olfactory receptor family 10 subfamily J member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of OR10J2 mRNA

NCBI chr 1:173,097,714...173,098,704
Ensembl chr 1:173,093,568...173,101,561

G

odd-skipped related 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of OSR2 mRNA

NCBI chr15:35,296,244...35,303,451
Ensembl chr15:35,296,244...35,303,451

G

3-oxoacid CoA transferase 2A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of OXCT2A mRNA

NCBI chr 4:123,215,668...123,217,472
Ensembl chr 4:123,215,668...123,217,427

G

purinergic receptor P2Y, G-protein coupled 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of P2RY10 mRNA

NCBI chr X:106,132,098...106,148,580
Ensembl chr X:106,132,098...106,148,580

G

procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 1 polypeptide

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of P4HA1 mRNA

NCBI chr10:59,159,019...59,209,126
Ensembl chr10:59,159,118...59,209,126

G

parvin, gamma

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PARVG mRNA

NCBI chr15:84,208,388...84,227,179
Ensembl chr15:84,208,227...84,227,179

G

paired box 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PAX5 mRNA

NCBI chr 4:44,524,748...44,710,694
Ensembl chr 4:44,524,757...44,710,487

G

paired box 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PAX6 mRNA

NCBI chr 2:105,499,241...105,528,755
Ensembl chr 2:105,499,245...105,527,709

G

phosphatidylethanolamine binding protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PBP2 mRNA

NCBI chr 6:135,286,127...135,287,382
Ensembl chr 6:135,286,125...135,287,403

G

protocadherin 15

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCDH15 mRNA

NCBI chr10:72,932,003...74,485,663
Ensembl chr10:72,935,174...74,485,569

G

protocadherin beta 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCDHB9 mRNA

NCBI chr18:37,533,908...37,536,962
Ensembl chr18:37,533,908...37,536,962

G

protocadherin gamma subfamily B, 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCDHGB1 mRNA

NCBI chr18:37,813,325...37,974,923
Ensembl chr18:37,813,286...37,974,923

G

PC-esterase domain containing 1B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCED1B mRNA

NCBI chr15:97,143,563...97,283,574
Ensembl chr15:97,144,988...97,283,561

G

proliferating cell nuclear antigen

increases expression

monomethylarsonic acid results in increased expression of PCNA mRNA

NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234

G

proprotein convertase subtilisin/kexin type 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCSK9 mRNA

NCBI chr 4:106,299,531...106,321,522
Ensembl chr 4:106,299,526...106,321,526

G

pleckstrin homology like domain, family A, member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PHLDA1 mRNA

NCBI chr10:111,342,147...111,344,510
Ensembl chr10:111,342,147...111,344,506

G

paired-like homeodomain transcription factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PITX1 mRNA

NCBI chr13:55,972,857...55,984,002
Ensembl chr13:55,972,864...55,984,005

G

phospholipase A2, group IIA (platelets, synovial fluid)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLA2G2A mRNA

NCBI chr 4:138,559,168...138,562,500
Ensembl chr 4:138,559,171...138,562,497

G

phospholipase A2, group IID

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLA2G2D mRNA

NCBI chr 4:138,503,046...138,509,363
Ensembl chr 4:138,503,046...138,509,357

G

phospholipase A2, group IVF

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLA2G4F mRNA

NCBI chr 2:120,130,433...120,144,646
Ensembl chr 2:120,130,438...120,144,646

G

plasminogen activator, urokinase receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLAUR mRNA

NCBI chr 7:24,161,857...24,175,393
Ensembl chr 7:24,161,909...24,175,393

G

phospholipase B1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLB1 mRNA

NCBI chr 5:32,390,035...32,521,700
Ensembl chr 5:32,390,052...32,523,864

G

phospholipase D family member 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLD4 mRNA

NCBI chr12:112,727,089...112,735,420
Ensembl chr12:112,727,089...112,735,424

G

pleckstrin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLEK mRNA

NCBI chr11:16,921,206...16,958,718
Ensembl chr11:16,921,206...17,002,381

G

pleckstrin homology domain containing, family G (with RhoGef domain) member 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLEKHG4 mRNA

NCBI chr 8:106,096,272...106,109,492
Ensembl chr 8:106,099,906...106,109,494

G

placenta expressed transcript 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLET1 mRNA

NCBI chr 9:50,405,825...50,416,939
Ensembl chr 9:50,405,825...50,416,782

G

placenta expressed transcript 1, opposite strand

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLET1OS mRNA

NCBI chr 9:50,400,099...50,416,105
Ensembl chr 9:50,400,083...50,419,123

G

polo like kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLK3 mRNA

NCBI chr 4:116,985,852...116,991,244
Ensembl chr 4:116,985,852...116,991,160

G

plexin C1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLXNC1 mRNA

NCBI chr10:94,626,728...94,780,875
Ensembl chr10:94,626,728...94,780,697

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PMAIP1 mRNA

NCBI chr18:66,591,675...66,598,629
Ensembl chr18:66,591,604...66,598,636

G

patatin-like phospholipase domain containing 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PNPLA1 mRNA

NCBI chr17:29,077,262...29,109,282
Ensembl chr17:29,077,385...29,109,283

G

patatin-like phospholipase domain containing 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PNPLA3 mRNA

NCBI chr15:84,052,017...84,073,720
Ensembl chr15:84,052,038...84,071,437

G

POU domain, class 2, associating factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of POU2AF1 mRNA

NCBI chr 9:51,124,990...51,151,379
Ensembl chr 9:51,125,008...51,151,380

G

POU domain, class 2, transcription factor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of POU2F2 mRNA

NCBI chr 7:24,790,111...24,879,292
Ensembl chr 7:24,786,769...24,879,151

G

protein phosphatase 1, regulatory subunit 16B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PPP1R16B mRNA

NCBI chr 2:158,508,653...158,608,254
Ensembl chr 2:158,507,318...158,608,254

G

PRAME like 34

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PRAMEL34 mRNA

NCBI chr 5:93,783,041...93,819,368
Ensembl chr 5:93,783,056...93,819,410

G

protein kinase C, alpha

increases expression

monomethylarsonic acid results in increased expression of PRKCA mRNA

NCBI chr11:107,824,213...108,237,360
Ensembl chr11:107,824,213...108,234,754

G

proline rich 5 like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PRR5L mRNA

NCBI chr 2:101,543,455...101,713,428
Ensembl chr 2:101,544,630...101,713,372

G

serine protease 16 (thymus)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PRSS16 mRNA

NCBI chr13:22,186,346...22,193,911
Ensembl chr13:22,186,343...22,193,912

G

phosphatase and tensin homolog

decreases expression

monomethylarsonic acid results in decreased expression of PTEN mRNA

NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560

G

prostaglandin F receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTGFR mRNA

NCBI chr 3:151,504,247...151,543,165
Ensembl chr 3:151,502,139...151,543,267

G

protein tyrosine phosphatase, non-receptor type 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTPN7 mRNA

NCBI chr 1:135,059,577...135,073,064
Ensembl chr 1:135,060,438...135,073,055

G

protein tyrosine phosphatase receptor type C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTPRC mRNA

NCBI chr 1:137,990,601...138,103,491
Ensembl chr 1:137,990,599...138,103,446

G

protein tyrosine phosphatase receptor type C polypeptide-associated protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTPRCAP mRNA

NCBI chr19:4,204,645...4,206,709
Ensembl chr19:4,203,603...4,206,750

G

pyroglutamylated RFamide peptide receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of QRFPR mRNA

NCBI chr 3:36,233,575...36,276,462
Ensembl chr 3:36,233,573...36,276,462

G

RAB33A, member RAS oncogene family

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RAB33A mRNA

NCBI chr X:47,602,540...47,619,112
Ensembl chr X:47,608,162...47,619,109

G

RAD51 paralog C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RAD51C mRNA

NCBI chr11:87,267,471...87,295,780
Ensembl chr11:87,267,471...87,295,780

G

RPA1 related single stranded DNA binding protein, X-linked

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RADX mRNA

NCBI chr X:138,381,116...138,455,333
Ensembl chr X:138,381,116...138,455,331

G

v-raf-leukemia viral oncogene 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of RAF1 mRNA

NCBI chr 6:115,595,530...115,653,596
Ensembl chr 6:115,595,028...115,653,596

G

RAS protein activator like 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RASAL3 mRNA

NCBI chr17:32,609,633...32,622,586
Ensembl chr17:32,609,633...32,622,557

G

RAS, dexamethasone-induced 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RASD1 mRNA

NCBI chr11:59,854,007...59,855,770
Ensembl chr11:59,854,007...59,855,770

G

RAS, guanyl releasing protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RASGRP3 mRNA

NCBI chr17:75,742,849...75,836,049
Ensembl chr17:75,742,891...75,836,049

G

RAS-like, family 11, member A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RASL11A mRNA

NCBI chr 5:146,781,881...146,784,536
Ensembl chr 5:146,781,881...146,784,537

G

retinol dehydrogenase 16

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RDH16 mRNA

NCBI chr10:127,636,959...127,651,715
Ensembl chr10:127,637,021...127,682,434

G

RDH16 family member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RDH16F2 mRNA

NCBI chr10:127,702,345...127,713,188
Ensembl chr10:127,702,343...127,713,186

G

REC114 meiotic recombination protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of REC114 mRNA

NCBI chr 9:58,560,139...58,729,684
Ensembl chr 9:58,560,133...58,651,247

G

REC8 meiotic recombination protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of REC8 mRNA

NCBI chr14:55,855,459...55,862,852
Ensembl chr14:55,855,494...55,862,852

G

receptor accessory protein 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of REEP6 mRNA

NCBI chr10:80,165,831...80,172,275
Ensembl chr10:80,165,787...80,172,275

G

regenerating islet-derived 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of REG2 mRNA

NCBI chr 6:78,382,138...78,385,082
Ensembl chr 6:78,372,606...78,385,089

G

regenerating islet-derived 3 beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of REG3B mRNA

NCBI chr 6:78,347,868...78,350,449
Ensembl chr 6:78,347,640...78,350,449

G

regenerating islet-derived 3 gamma

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of REG3G mRNA

NCBI chr 6:78,443,252...78,445,857
Ensembl chr 6:78,443,252...78,445,855

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of RELA mRNA

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

RELT-like 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RELL2 mRNA

NCBI chr18:38,088,107...38,092,232
Ensembl chr18:38,088,132...38,092,232

G

resistin like alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RETNLA mRNA

NCBI chr16:48,662,972...48,664,824
Ensembl chr16:48,662,914...48,664,824

G

ral guanine nucleotide dissociation stimulator-like 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RGL3 mRNA

NCBI chr 9:21,882,475...21,900,765
Ensembl chr 9:21,880,007...21,900,742

G

regulator of G-protein signaling 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RGS1 mRNA

NCBI chr 1:144,120,407...144,124,862
Ensembl chr 1:144,118,034...144,124,980

G

ras homolog family member H

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RHOH mRNA

NCBI chr 5:66,018,092...66,054,043
Ensembl chr 5:66,018,556...66,054,043

G

receptor-interacting serine-threonine kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RIPK3 mRNA

NCBI chr14:56,022,452...56,026,314
Ensembl chr14:56,022,452...56,026,322

G

RHO family interacting cell polarization regulator 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RIPOR2 mRNA

NCBI chr13:24,685,513...24,917,789
Ensembl chr13:24,685,508...24,917,799

G

ribonuclease, RNase A family, 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RNASE6 mRNA

NCBI chr14:51,361,365...51,369,644
Ensembl chr14:51,361,365...51,369,644

G

ring finger protein 225

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RNF225 mRNA

NCBI chr 7:12,661,343...12,664,999
Ensembl chr 7:12,661,343...12,664,999

G

ring finger protein 24

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RNF24 mRNA

NCBI chr 2:131,139,984...131,194,766
Ensembl chr 2:131,139,984...131,194,812

G

Ros1 proto-oncogene

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ROS1 mRNA

NCBI chr10:51,920,959...52,071,494
Ensembl chr10:51,921,817...52,071,340

G

ribonuclease P RNA component H1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of RPPH1 mRNA

NCBI chr14:51,044,904...51,045,228
Ensembl chr14:51,044,906...51,045,224

G

ribosomal protein S6 kinase related

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RSKR mRNA

NCBI chr11:78,181,580...78,187,631
Ensembl chr11:78,181,667...78,187,631

G

RUN and cysteine rich domain containing beclin 1 interacting protein like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RUBCNL mRNA

NCBI chr14:75,253,467...75,289,977
Ensembl chr14:75,253,467...75,289,972

G

ryanodine receptor 1, skeletal muscle

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RYR1 mRNA

NCBI chr 7:28,702,765...28,824,599
Ensembl chr 7:28,702,769...28,824,604

G

ryanodine receptor 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RYR3 mRNA

NCBI chr 2:112,461,699...113,047,755
Ensembl chr 2:112,461,700...113,047,441

G

S100 calcium binding protein G

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of S100G mRNA

NCBI chr X:161,744,988...161,747,595
Ensembl chr X:161,744,988...161,747,595

G

sphingosine-1-phosphate receptor 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of S1PR4 mRNA

NCBI chr10:81,333,579...81,335,971
Ensembl chr10:81,333,581...81,335,966

G

sacsin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SACS mRNA

NCBI chr14:61,375,870...61,478,142
Ensembl chr14:61,375,906...61,478,144

G

sterile alpha motif domain containing 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SAMD4 mRNA

NCBI chr14:47,120,414...47,343,274
Ensembl chr14:47,120,311...47,343,272

G

SAM domain, SH3 domain and nuclear localization signals, 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SAMSN1 mRNA

NCBI chr16:75,655,682...75,706,154
Ensembl chr16:75,655,681...75,819,169

G

SAM and SH3 domain containing 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SASH3 mRNA

NCBI chr X:47,235,313...47,250,442
Ensembl chr X:47,235,313...47,250,442

G

sciellin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SCEL mRNA

NCBI chr14:103,750,499...103,850,782
Ensembl chr14:103,750,778...103,850,233

G

sodium channel, voltage-gated, type IV, alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SCN4A mRNA

NCBI chr11:106,208,374...106,256,385
Ensembl chr11:106,209,418...106,244,114

G

secreted and transmembrane 1A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SECTM1A mRNA

NCBI chr11:120,958,221...120,988,023
Ensembl chr11:120,958,233...120,972,046

G

selectin, lymphocyte

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SELL mRNA

NCBI chr 1:163,889,556...163,908,354
Ensembl chr 1:163,889,551...163,911,750

G

sema domain, immunoglobulin domain (Ig), and GPI membrane anchor, (semaphorin) 7A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SEMA7A mRNA

NCBI chr 9:57,846,879...57,870,148
Ensembl chr 9:57,847,395...57,870,148

G

serine (or cysteine) preptidase inhibitor, clade A, member 1B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SERPINA1B mRNA

NCBI chr12:103,694,415...103,704,448
Ensembl chr12:103,694,415...103,796,632

G

serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SERPINC1 mRNA

NCBI chr 1:160,806,153...160,830,113
Ensembl chr 1:160,806,155...160,833,433

G

serine (or cysteine) peptidase inhibitor, clade F, member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SERPINF2 mRNA

NCBI chr11:75,322,562...75,330,327
Ensembl chr11:75,322,558...75,330,417

G

secreted frizzled-related protein 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SFRP4 mRNA

NCBI chr13:19,807,345...19,816,995
Ensembl chr13:19,807,274...19,817,164

G

serum/glucocorticoid regulated kinase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SGK1 mRNA

NCBI chr10:21,758,083...21,875,802
Ensembl chr10:21,758,083...21,875,802

G

SH3 domain containing 21

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SH3D21 mRNA

NCBI chr 4:126,044,395...126,057,503
Ensembl chr 4:126,044,395...126,057,284

G

shroom family member 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SHROOM4 mRNA

NCBI chr X:6,312,012...6,549,508
Ensembl chr X:6,311,908...6,549,502

G

sialic acid binding Ig-like lectin G

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SIGLECG mRNA

NCBI chr 7:43,057,623...43,067,773
Ensembl chr 7:43,057,628...43,067,782

G

signaling lymphocytic activation molecule family member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLAMF1 mRNA

NCBI chr 1:171,594,700...171,628,752
Ensembl chr 1:171,594,695...171,628,752

G

SLAM family member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLAMF6 mRNA

NCBI chr 1:171,745,002...171,776,525
Ensembl chr 1:171,745,082...171,780,737

G

SLAM family member 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLAMF7 mRNA

NCBI chr 1:171,458,506...171,480,522
Ensembl chr 1:171,459,971...171,480,603

G

solute carrier family 10 (sodium/bile acid cotransporter family), member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC10A1 mRNA

NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479

G

solute carrier family 10 (sodium/bile acid cotransporter family), member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC10A6 mRNA

NCBI chr 5:103,753,583...103,777,152
Ensembl chr 5:103,753,577...103,777,269

G

solute carrier family 13 (sodium/sulfate symporters), member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC13A1 mRNA

NCBI chr 6:24,088,282...24,168,118
Ensembl chr 6:24,088,282...24,168,091

G

solute carrier family 14 (urea transporter), member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC14A1 mRNA

NCBI chr18:78,143,306...78,185,334
Ensembl chr18:78,143,306...78,185,334

G

solute carrier family 15, member 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC15A5 mRNA

NCBI chr 6:137,960,584...138,056,914
Ensembl chr 6:137,960,584...138,056,914

G

solute carrier family 16 (monocarboxylic acid transporters), member 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC16A8 mRNA

NCBI chr15:79,135,216...79,139,619
Ensembl chr15:79,135,214...79,138,961

G

solute carrier family 26 (sulfate transporter), member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC26A2 mRNA

NCBI chr18:61,329,926...61,344,668
Ensembl chr18:61,325,991...61,344,684

G

solute carrier family 27 (fatty acid transporter), member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC27A3 mRNA

NCBI chr 3:90,292,540...90,298,693
Ensembl chr 3:90,292,546...90,297,245

G

solute carrier family 28 (sodium-coupled nucleoside transporter), member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC28A2 mRNA

NCBI chr 2:122,256,836...122,291,633
Ensembl chr 2:122,256,958...122,291,618

G

solute carrier family 28 (sodium-coupled nucleoside transporter), member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC28A3 mRNA

NCBI chr13:58,701,121...58,758,691
Ensembl chr13:58,693,213...58,758,691

G

solute carrier family 29 (nucleoside transporters), member 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC29A4 mRNA

NCBI chr 5:142,678,226...142,708,245
Ensembl chr 5:142,678,267...142,708,245

G

solute carrier family 2 (facilitated glucose transporter), member 1

increases import

SLC2A1 protein results in increased import of monomethylarsonic acid

NCBI chr 4:118,966,001...118,994,527
Ensembl chr 4:118,965,908...118,995,180

G

Slc2a4 regulator, pseudogene

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC2A4RG-PS mRNA

NCBI chr 2:181,026,043...181,029,389
Ensembl chr 2:181,026,043...181,029,390
Ensembl chr 2:181,026,043...181,029,390

G

solute carrier family 2 (facilitated glucose transporter), member 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC2A5 mRNA

NCBI chr 4:150,203,801...150,228,625
Ensembl chr 4:150,203,740...150,228,626

G

solute carrier family 34 (sodium phosphate), member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC34A2 mRNA

NCBI chr 5:53,206,695...53,229,006
Ensembl chr 5:53,195,423...53,229,006

G

solute carrier family 38, member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC38A3 mRNA

NCBI chr 9:107,528,353...107,546,167
Ensembl chr 9:107,527,833...107,546,729

G

solute carrier family 38, member 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC38A8 mRNA

NCBI chr 8:120,206,313...120,228,503
Ensembl chr 8:120,206,341...120,228,437

G

solute carrier family 39 (zinc transporter), member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC39A2 mRNA

NCBI chr14:52,130,539...52,134,202
Ensembl chr14:52,130,346...52,134,202

G

solute carrier family 41, member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC41A3 mRNA

NCBI chr 6:90,579,043...90,623,394
Ensembl chr 6:90,581,707...90,623,394

G

solute carrier family 5 (inositol transporters), member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC5A3 mRNA

NCBI chr16:91,855,210...91,884,361
Ensembl chr16:91,855,210...91,884,361

G

solute carrier family 5 (sodium/glucose cotransporter), member 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC5A9 mRNA

NCBI chr 4:111,732,571...111,759,993
Ensembl chr 4:111,732,572...111,760,115

G

solute carrier family 6 (neurotransmitter transporter), member 18

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC6A18 mRNA

NCBI chr13:73,809,869...73,826,142
Ensembl chr13:73,809,871...73,826,142

G

solute carrier family 6 (neurotransmitter transporter), member 20A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC6A20A mRNA

NCBI chr 9:123,465,972...123,507,897
Ensembl chr 9:123,463,835...123,507,950

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC7A9 mRNA

NCBI chr 7:35,148,152...35,165,459
Ensembl chr 7:35,148,221...35,165,461

G

solute carrier family 8 (sodium/calcium exchanger), member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC8A3 mRNA

NCBI chr12:81,244,686...81,380,506
Ensembl chr12:81,244,689...81,379,954

G

solute carrier family 9 (sodium/hydrogen exchanger), member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC9A3 mRNA

NCBI chr13:74,234,374...74,317,561
Ensembl chr13:74,269,576...74,317,561

G

solute carrier organic anion transporter family, member 5A1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLCO5A1 mRNA

NCBI chr 1:12,936,773...13,063,043
Ensembl chr 1:12,936,773...13,062,874

G

schlafen 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLFN8 mRNA

NCBI chr11:82,892,984...82,911,636
Ensembl chr11:82,892,984...82,911,636

G

stannin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SNN mRNA

NCBI chr16:10,884,162...10,892,849
Ensembl chr16:10,878,809...10,892,849

G

sterol O-acyltransferase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SOAT2 mRNA

NCBI chr15:102,058,853...102,071,871
Ensembl chr15:102,058,961...102,071,904

G

superoxide dismutase 1, soluble

increases expression

monomethylarsonic acid results in increased expression of SOD1 mRNA

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

G

superoxide dismutase 2, mitochondrial

increases expression

monomethylarsonic acid results in increased expression of SOD2 mRNA

NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950

G

Sox1 overlapping transcript

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SOX1OT mRNA

NCBI chr 8:12,435,771...12,486,732
Ensembl chr 8:12,435,771...12,486,768

G

Sp140 nuclear body protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SP140 mRNA

NCBI chr 1:85,515,212...85,572,761
Ensembl chr 1:85,528,099...85,572,758

G

sperm associated antigen 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPAG1 mRNA

NCBI chr15:36,175,629...36,235,767
Ensembl chr15:36,178,245...36,235,767

G

spermatogenesis associated 6 like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SPATA6L mRNA

NCBI chr19:28,899,836...28,945,289
Ensembl chr19:28,878,668...28,945,200

G

spermatogenesis associated, serine-rich 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPATS1 mRNA

NCBI chr17:45,754,156...45,785,864
Ensembl chr17:45,751,504...45,786,341

G

small proline-rich protein 1A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPRR1A mRNA

NCBI chr 3:92,391,261...92,393,188
Ensembl chr 3:92,391,259...92,393,202

G

small proline-rich protein 2A3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPRR2A3 mRNA

NCBI chr 3:92,192,611...92,196,571
Ensembl chr 3:92,192,724...92,198,712

G

small proline-rich protein 2H

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPRR2H mRNA

NCBI chr 3:92,292,992...92,294,631
Ensembl chr 3:92,292,992...92,294,631

G

sprouty RTK signaling antagonist 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPRY4 mRNA

NCBI chr18:38,719,300...38,734,400
Ensembl chr18:38,719,300...38,734,468

G

serine palmitoyltransferase, small subunit B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPTSSB mRNA

NCBI chr 3:69,726,871...69,768,697
Ensembl chr 3:69,726,875...69,767,273

G

squalene epoxidase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SQLE mRNA

NCBI chr15:59,186,941...59,203,042
Ensembl chr15:59,186,926...59,203,041

G

Rous sarcoma oncogene

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of SRC mRNA

NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782

G

sterol regulatory element binding factor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SREBF2 mRNA

NCBI chr15:82,031,455...82,089,580
Ensembl chr15:82,031,382...82,089,580

G

serine/arginine-rich protein specific kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SRPK3 mRNA

NCBI chr X:72,818,011...72,822,531
Ensembl chr X:72,818,011...72,822,531

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ST3GAL4 mRNA

NCBI chr 9:34,957,872...35,028,160
Ensembl chr 9:34,957,872...35,030,564

G

ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ST6GALNAC3 mRNA

NCBI chr 3:152,903,911...153,430,804
Ensembl chr 3:152,903,903...153,430,811

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ST8SIA4 mRNA

NCBI chr 1:95,515,407...95,595,473
Ensembl chr 1:95,515,407...95,595,296

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ST8SIA6 mRNA

NCBI chr 2:13,659,745...13,798,659
Ensembl chr 2:13,655,832...13,798,875

G

signal transducing adaptor family member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of STAP1 mRNA

NCBI chr 5:86,219,446...86,251,859
Ensembl chr 5:86,219,605...86,253,984

G

signal transducer and activator of transcription 3

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of STAT3 mRNA

NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366

G

sushi domain containing 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SUSD3 mRNA

NCBI chr13:49,378,993...49,402,197
Ensembl chr13:49,384,166...49,402,182

G

synaptonemal complex protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SYCP2 mRNA

NCBI chr 2:177,987,088...178,051,580
Ensembl chr 2:177,987,086...178,049,478

G

syncytin a

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SYNA mRNA

NCBI chr 5:134,586,108...134,605,891
Ensembl chr 5:134,587,000...134,589,025

G

synaptotagmin V

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SYT5 mRNA

NCBI chr 7:4,542,764...4,550,540
Ensembl chr 7:4,542,764...4,550,540

G

synaptotagmin VIII

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SYT8 mRNA

NCBI chr 7:141,988,195...141,994,136
Ensembl chr 7:141,988,587...141,994,133

G

TBC1 domain family, member 10c

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TBC1D10C mRNA

NCBI chr19:4,234,356...4,241,194
Ensembl chr19:4,233,410...4,241,283

G

T-box 3, opposite strand 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TBX3OS1 mRNA

NCBI chr 5:119,708,194...119,809,573
Ensembl chr 5:119,708,195...119,809,430
Ensembl chr 5:119,708,195...119,809,430

G

transcription factor 23

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TCF23 mRNA

NCBI chr 5:31,125,946...31,145,406
Ensembl chr 5:31,126,006...31,134,362

G

transcription factor 24

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TCF24 mRNA

NCBI chr 1:10,030,388...10,038,207
Ensembl chr 1:10,030,388...10,038,157

G

t-complex protein 10a

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TCP10A mRNA

NCBI chr17:7,592,055...7,613,259
Ensembl chr17:7,592,045...7,613,373

G

terminal nucleotidyltransferase 5B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TENT5B mRNA

NCBI chr 4:133,207,444...133,215,251
Ensembl chr 4:133,207,443...133,215,249

G

thymocyte expressed, positive selection associated 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TESPA1 mRNA

NCBI chr10:130,158,696...130,199,338
Ensembl chr10:130,158,739...130,199,980

G

testis expressed gene 19.1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TEX19.1 mRNA

NCBI chr11:121,036,969...121,039,140
Ensembl chr11:121,036,969...121,039,145

G

transforming growth factor, beta 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of TGFB1 mRNA

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

transforming growth factor, beta receptor II

increases expression

monomethylarsonic acid results in increased expression of TGFBR2 mRNA

NCBI chr 9:115,916,763...116,004,431
Ensembl chr 9:115,913,361...116,004,428

G

transglutaminase 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TGM7 mRNA

NCBI chr 2:120,923,979...120,946,877
Ensembl chr 2:120,924,046...120,946,877

G

thrombomodulin

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of THBD mRNA

NCBI chr 2:148,246,391...148,250,108
Ensembl chr 2:148,246,386...148,250,108

G

thymocyte selection associated

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of THEMIS mRNA

NCBI chr10:28,544,356...28,759,816
Ensembl chr10:28,544,356...28,759,814

G

TRAF-interacting protein with forkhead-associated domain

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TIFA mRNA

NCBI chr 3:127,582,524...127,592,043
Ensembl chr 3:127,583,454...127,625,813

G

toll-like receptor 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TLR8 mRNA

NCBI chr X:166,024,119...166,047,325
Ensembl chr X:166,025,692...166,047,325

G

toll-like receptor 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TLR9 mRNA

NCBI chr 9:106,099,797...106,104,075
Ensembl chr 9:106,099,797...106,104,082

G

transmembrane 4 L six family member 20

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TM4SF20 mRNA

NCBI chr 1:82,734,368...82,746,182
Ensembl chr 1:82,734,370...82,746,182

G

transmembrane p24 trafficking protein 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TMED6 mRNA

NCBI chr 8:107,788,116...107,792,276
Ensembl chr 8:107,788,108...107,792,276

G

transmembrane protein 140

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TMEM140 mRNA

NCBI chr 6:34,840,081...34,851,881
Ensembl chr 6:34,840,081...34,851,881

G

transmembrane protein 156

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TMEM156 mRNA

NCBI chr 5:65,215,558...65,249,524
Ensembl chr 5:65,211,689...65,249,475

G

transmembrane protein 17

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TMEM17 mRNA

NCBI chr11:22,462,283...22,469,231
Ensembl chr11:22,462,088...22,469,234

G

transmembrane protein 266

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TMEM266 mRNA

NCBI chr 9:55,234,194...55,345,629
Ensembl chr 9:55,234,197...55,345,629

G

transmembrane protein 71

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TMEM71 mRNA

NCBI chr15:66,398,061...66,433,085
Ensembl chr15:66,398,061...66,432,952

G

tumor necrosis factor receptor superfamily, member 13b

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNFRSF13B mRNA

NCBI chr11:61,017,567...61,040,435
Ensembl chr11:61,017,581...61,040,198

G

tumor necrosis factor receptor superfamily, member 13c

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNFRSF13C mRNA

NCBI chr15:82,105,943...82,108,581
Ensembl chr15:82,105,944...82,108,570

G

tumor necrosis factor receptor superfamily, member 1a

decreases expression

monomethylarsonic acid results in decreased expression of TNFRSF1A mRNA

NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447

G

tumor necrosis factor receptor superfamily, member 25

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TNFRSF25 mRNA

NCBI chr 4:152,199,985...152,204,568
Ensembl chr 4:152,200,391...152,204,576

G

tumor necrosis factor (ligand) superfamily, member 11

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNFSF11 mRNA

NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483

G

tumor necrosis factor (ligand) superfamily, member 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNFSF8 mRNA

NCBI chr 4:63,749,439...63,779,745
Ensembl chr 4:63,749,545...63,779,584

G

troponin I, skeletal, fast 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNNI2 mRNA

NCBI chr 7:141,995,553...141,998,147
Ensembl chr 7:141,995,545...141,998,147

G

troponin T3, skeletal, fast

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNNT3 mRNA

NCBI chr 7:142,052,530...142,069,746
Ensembl chr 7:142,052,573...142,069,746

G

tubulin polymerization promoting protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TPPP mRNA

NCBI chr13:74,157,538...74,183,872
Ensembl chr13:74,157,526...74,183,872

G

transformer 2 alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TRA2A mRNA

NCBI chr 6:49,220,855...49,241,182
Ensembl chr 6:49,220,858...49,240,967

G

TNF receptor-associated factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRAF1 mRNA

NCBI chr 2:34,831,762...34,851,784
Ensembl chr 2:34,831,762...34,851,784

G

TNF receptor-associated factor 3

decreases expression

monomethylarsonic acid results in decreased expression of TRAF3 mRNA

NCBI chr12:111,132,799...111,233,589
Ensembl chr12:111,132,804...111,233,587

G

TRAF3 interacting protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRAF3IP3 mRNA

NCBI chr 1:192,857,812...192,883,854
Ensembl chr 1:192,857,761...192,884,011

G

tetratricopeptide repeat and ankyrin repeat containing 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRANK1 mRNA

NCBI chr 9:111,140,351...111,224,843
Ensembl chr 9:111,140,807...111,224,843

G

T cell receptor associated transmembrane adaptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TRAT1 mRNA

NCBI chr16:48,551,137...48,630,883
Ensembl chr16:48,551,137...48,592,384

G

T cell receptor beta, constant region 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRBC1 mRNA

NCBI chr 6:41,515,153...41,516,599
Ensembl chr 6:41,515,152...41,516,815

G

tripartite motif-containing 30B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRIM30B mRNA

NCBI chr 7:104,004,605...104,007,853
Ensembl chr 7:104,004,589...104,019,091

G

tripartite motif-containing 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TRIM6 mRNA

NCBI chr 7:103,868,002...103,884,359
Ensembl chr 7:103,868,000...103,884,359

G

tRNA methyltransferase 11-2, pseudogene 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TRMT112-PS1 mRNA

NCBI chr 5:91,885,389...91,885,972
Ensembl chr 5:91,885,564...91,885,938

G

transformation related protein 53

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of TP53 mRNA

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

transient receptor potential cation channel, subfamily C, member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRPC3 mRNA

NCBI chr 3:36,674,626...36,744,276
Ensembl chr 3:36,674,631...36,744,316

G

transient receptor potential cation channel, subfamily V, member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRPV3 mRNA

NCBI chr11:73,158,315...73,191,194
Ensembl chr11:73,158,214...73,191,189

G

transient receptor potential cation channel, subfamily V, member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRPV6 mRNA

NCBI chr 6:41,597,553...41,613,339
Ensembl chr 6:41,597,558...41,613,339

G

tetraspanin 32

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TSPAN32 mRNA

NCBI chr 7:142,558,644...142,573,223
Ensembl chr 7:142,558,783...142,573,381

G

tetratricopeptide repeat domain 41

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TTC41 mRNA

NCBI chr10:86,541,675...86,612,708
Ensembl chr10:86,541,675...86,612,708

G

tubulin tyrosine ligase-like family, member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TTLL2 mRNA

NCBI chr17:7,618,026...7,631,434
Ensembl chr17:7,618,284...7,620,095

G

tubulin tyrosine ligase-like family, member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TTLL3 mRNA

NCBI chr 6:113,366,221...113,391,553
Ensembl chr 6:113,366,221...113,391,548

G

tubulin tyrosine ligase-like family, member 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TTLL9 mRNA

NCBI chr 2:152,792,966...152,850,402
Ensembl chr 2:152,804,405...152,850,402

G

tweety family member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TTYH3 mRNA

NCBI chr 5:140,606,332...140,634,826
Ensembl chr 5:140,606,333...140,634,786

G

TXK tyrosine kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TXK mRNA

NCBI chr 5:72,853,321...72,910,337
Ensembl chr 5:72,853,321...72,910,120

G

thioredoxin 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of TXN mRNA

NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411

G

thioredoxin reductase 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of TXNRD1 mRNA

NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546

G

uncoupling protein 2 (mitochondrial, proton carrier)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of UCP2 mRNA

NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227

G

UDP glucuronosyltransferase 1 family, polypeptide A2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of UGT1A2 mRNA

NCBI chr 1:88,128,333...88,147,724
Ensembl chr 1:88,128,323...88,146,719

G

UDP glucuronosyltransferase 1 family, polypeptide A5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of UGT1A5 mRNA

NCBI chr 1:88,093,734...88,147,724
Ensembl chr 1:88,093,734...88,146,719

G

UL16 binding protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ULBP1 mRNA

NCBI chr10:7,394,873...7,423,643
Ensembl chr10:7,390,362...7,423,638

G

vascular cell adhesion molecule 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of VCAM1 mRNA

NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337

G

vascular endothelial growth factor A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of VEGFA mRNA

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

G

vomeronasal 1 receptor 91

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of VMN1R91 mRNA

NCBI chr 7:19,835,083...19,836,006
Ensembl chr 7:19,833,605...19,837,026

G

vanin 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of VNN1 mRNA

NCBI chr10:23,770,586...23,781,242
Ensembl chr10:23,770,586...23,781,241

G

V-set pre-B cell surrogate light chain 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of VPREB3 mRNA

NCBI chr10:75,778,859...75,785,491
Ensembl chr10:75,778,891...75,785,491

G

vacuolar protein sorting 25

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of VPS25 mRNA

NCBI chr11:101,144,533...101,150,377
Ensembl chr11:101,144,533...101,150,375

G

Wiskott-Aldrich syndrome

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of WAS mRNA

NCBI chr X:7,947,705...7,956,730
Ensembl chr X:7,947,692...7,956,737

G

WD repeat and FYVE domain containing 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of WDFY4 mRNA

NCBI chr14:32,681,504...32,915,809
Ensembl chr14:32,681,504...32,907,465

G

WD repeat domain 31

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of WDR31 mRNA

NCBI chr 4:62,366,890...62,389,236
Ensembl chr 4:62,366,890...62,389,133

G

WD repeat domain 54

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of WDR54 mRNA

NCBI chr 6:83,129,691...83,133,383
Ensembl chr 6:83,126,342...83,133,379

G

wingless-type MMTV integration site family, member 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of WNT1 mRNA

NCBI chr15:98,687,738...98,691,711
Ensembl chr15:98,687,738...98,691,718

G

X-linked Kx blood group related 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of XKR8 mRNA

NCBI chr 4:132,452,212...132,459,916
Ensembl chr 4:132,452,208...132,459,857

G

X-linked lymphocyte-regulated 4C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of XLR4C mRNA

NCBI chr X:72,277,682...72,286,736
Ensembl chr X:72,277,294...72,286,736

G

X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of XPNPEP2 mRNA

NCBI chr X:47,195,790...47,225,859
Ensembl chr X:47,197,602...47,225,858

G

zeta-chain (TCR) associated protein kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZAP70 mRNA

NCBI chr 1:36,800,912...36,821,899
Ensembl chr 1:36,800,879...36,821,899

G

zinc finger and BTB domain containing 16

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ZBTB16 mRNA

NCBI chr 9:48,563,097...48,747,525
Ensembl chr 9:48,565,597...48,747,522

G

zinc finger and BTB domain containing 40

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ZBTB40 mRNA

NCBI chr 4:136,707,043...136,776,129
Ensembl chr 4:136,707,043...136,776,112

G

zinc finger CCCH type containing 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZC3H6 mRNA

NCBI chr 2:128,809,285...128,860,483
Ensembl chr 2:128,809,322...128,860,483

G

zinc finger, DHHC domain containing 19

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZDHHC19 mRNA

NCBI chr16:32,315,059...32,326,032
Ensembl chr16:32,315,083...32,380,784

G

zinc finger homeobox 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ZFHX2 mRNA

NCBI chr14:55,297,722...55,329,875
Ensembl chr14:55,297,719...55,329,781

G

zinc finger protein 433

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZFP433 mRNA

NCBI chr10:81,540,581...81,562,021
Ensembl chr10:81,540,659...81,562,520

G

zinc finger protein 503

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZFP503 mRNA

NCBI chr14:22,034,030...22,039,669
Ensembl chr14:22,034,027...22,039,669

G

zinc finger protein 607B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ZFP607B mRNA

NCBI chr 7:27,374,086...27,405,909
Ensembl chr 7:27,388,765...27,405,909

G

zinc finger protein 773

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ZFP773 mRNA

NCBI chr 7:7,133,677...7,139,754
Ensembl chr 7:7,130,072...7,139,754

G

zinc finger protein 831

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZFP831 mRNA

NCBI chr 2:174,440,453...174,552,625
Ensembl chr 2:174,485,327...174,552,625

G

zinc finger protein 92

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZFP92 mRNA

NCBI chr X:72,454,555...72,473,980
Ensembl chr X:72,454,702...72,471,991

G

zinc finger protein 950

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ZFP950 mRNA

NCBI chr19:61,042,692...61,129,297
Ensembl chr19:61,042,278...61,129,278

G

zinc finger protein 993

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZFP993 mRNA

NCBI chr 4:146,695,318...146,742,868
Ensembl chr 4:146,695,418...146,742,617

G

zinc finger, matrin type 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZMAT4 mRNA

NCBI chr 8:24,137,347...24,553,133
Ensembl chr 8:24,126,035...24,646,601

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	22182
chemical entity	22181
atom	22174
nonmetal atom	22059
carbon atom	21835
organic molecular entity	21835
one-carbon compound	18572
methylarsonic acid	730
Path 2
Term	Annotations
CHEBI ontology	22182
subatomic particle	22174
composite particle	22174
hadron	22174
baryon	22174
nucleon	22174
atomic nucleus	22174
atom	22174
main group element atom	22108
p-block element atom	22108
chalcogen	21441
oxygen atom	21419
oxygen molecular entity	21419
hydroxides	20799
oxoacid	20118
pnictogen oxoacid	13685
arsenic oxoacid	4423
arsonic acids	747
arsonic acid	747
organoarsonic acid	747
methylarsonic acid	730

paths to the root